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ABSTRACT 
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Thesis supervisor: Batu Erman 
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Transcription activator-like effector, TALEN, Genome Editing 
 
 
IL-7 signaling is key to lymphocyte development and function in the mammalian 
immune system. In the first part of this study, we targeted the IL-7R alpha gene locus, 
encoding the IL-7 receptor protein, to identify its transcriptional control elements. We 
mutated two transcription factor binding sites in an evolutionarily conserved region 
containing a putative transcriptional enhancer by generating transcription activator like 
effector nucleases (TALENs) targeting these sites. We designed and constructed two 
pairs of TALENs targeting the glucocorticoid receptor (GR) and Notch binding sites in 
this region. We also targeted the exon 2 and exon 3 of IL-7R to delete a transcriptional 
control element in intron 2. We expressed these TALENs in the murine RLM11 (IL-7R 
positive) cell line and generated insertion and deletion mutations in the targeted sites. 
We used restriction fragment length polymorphism (RFLP) assays and DNA 
sequencing to detect the induced mutations and assessed their effects on IL-7R gene 
expression. We demonstrate that mutations induced in the GR transcription factor 
binding site do not reduce IL-7R gene expression, while mutations in the Notch binding 
site lower expression. In the second part of the study we directly targeted the gene 
encoding the GR transcription factor. We designed a TALEN pair targeting the 
translation start site to knockout gene expression. We introduced these TALENs into the 
human HCT116 cell line and performed RFLP assays to detect mutations. Our 
experiments demonstrate that TALENs can be used for genome editing to study gene 
transcription regulatory regions. 
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ÖZET 
 
 
IL-7 ALMAÇ GENİNDE  
TALEN PROTEİNLERİ İLE GENOM MÜHENDİSLİĞİ 
 
 
Gülperi Yalçın 
Biyoloji Bilimleri ve Biyomühendislik, Master Tezi, 2014 
Tez Danışmanı: Batu Erman 
 
 
Anahtar Kelimeler: IL-7R alfa, Glukokortikoid Almacı, 
Transcription activator-like effector, TALEN, Genom Mühendisliği 
 
 
IL-7 sinyallemesi memeli bağışıklık sisteminde lenfosit gelişimi ve fonksiyonu için 
anahtar konumundadır. Bu çalışmanın ilk bölümünde IL-7R alfa gen bölgesini 
hedefleyip gen ifadesini kontrol eden faktörleri tespit etmeyi amaçladık. Transcription 
activator-like effector nükleaz (TALEN) proteinleri ile enhancer bölgesindeki iki 
transkripsiyon faktör bağlanma bölgesinde mütasyonlar oluşturduk. Glukokortikoid 
almacı (GR) ve Notch bağlanma bölgelerini hedefleyen iki çift TALEN ile birlikte 2. ve 
3. ekzon bölgelerini hedefleyen TALEN’ler oluşturup aralarındaki intron bölgesindeki 
transkripsiyon kontrol elementlerini genomdan silmeyi planladık. Bu TALEN’leri fare 
RLM11 (IL-7R+) hücre hattında ifade edip RFLP yöntemi ve DNA sekanslaması ile 
oluşturduğumuz mütasyonları tespit ettik. Mutant hücre hatlarının IL-7R ifadelerini 
analiz ederek Notch bağlanma bölgesindeki mütasyonların gen ifadesinde azalmaya yol 
açtığını, fakat GR bağlanma bölgesindeki mütasyonların bu ifade seviyesini 
düşüremediğini gözlemledik. Çalışmanın ikinci bölümünde doğrudan GR transkripsiyon 
faktörünün gen bölgesini hedefledik. Translasyon başlangıç bölgesinde çift sarmallı 
kesik oluşturacak bir TALEN çifti tasarlayıp gen “knockout” yapmayı amaçladık. Bu 
TALEN’leri insan HCT116 hücre hattında ifade edip RFLP ile mütasyonları tespit ettik. 
Deneylerimiz TALEN teknolojisi ile genomun modifiye edilip gen ifadesini kontrol 
eden faktörlerin çalışılabileceğini göstermektedir. 
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1.  INTRODUCTION 
 
 
1.1 Transcription Activator like Effectors 
Gram-negative bacterial plant pathogens of the Xanthomonas genus mostly owe 
their pathogenicity to the Hrp-Type III secretion (T3S) system which translocates 
effector proteins into plant cells. The largest effector family consist of transcription 
activator like (TAL) effectors which functions as transcription activators of plant genes. 
With the help of a nuclear localization signal TALE proteins translocate to the nucleus 
and bind targeted promoters in the host genome to perform a variety of tasks to promote 
bacterial infection, proliferation and dissemination 1.  
 
1.1.1 Structural Features of TAL Effector Proteins 
A typical TALE structure is composed of an N-terminal translocation domain 
(TD), a central DNA binding domain (DBD), two nuclear localization signals (NLS) 
and a transcriptional activation domain (AD) in the C-terminal region. The DNA 
binding domain is made up of several tandem repeats and a final half-repeat as it is 
shown in Figure 1.1. Each repeat module generally is 34 amino acids (aa) in length; the 
last C-terminal half-repeat consists of 20 aa. The repeats are highly conserved; but the 
residues at positions 12 and 13 are polymorphic and called ‘repeat-variable di-residue’ 
(RVD). These two residues are responsible for recognizing and binding the specific 
DNA base pairs.  
 
 
1 
 
Figure 1.1 TALE structure and DNA recognition code. The transcription activator-like 
effector structure has an N-terminal translocation domain (TD), an array of repeats as a 
DBD, two NLS and an activation domain at the C-terminal. Each repeat in the DBD 
consists of the same 34 amino acid sequence with the exception of the 12th and 13th 
aminoacids, called repeat-variable di-residues (RVDs). Each RVD recognizes a 
different base of nucleotides. In the sketch, color coded four common RVDs and the 
target sequence they would bind is shown as an example 2. 
 
 
The number of repeats and their order changes the sequence TAL effectors bind, 
and this is mediated by a code. This code was deciphered by independent groups, and 
commonly found RVDs HD, NG/HG and NI has been proven to bind specifically to 
cytosine, thymine and adenine respectively. There are also other RVDs that are not 
exclusive, NN was found to recognize both adenine and guanine while NS could bind 
all four of the bases. Bioinformatic studies done with a large variety of TAL repeats has 
shown that the order of the repeats do not have a significant pattern and the binding 
specificity of one repeat does not affect the neighboring one 3,4. However, most of the 
natural target sites had a conserved thymine in position zero (the base preceding the first 
base pair recognized by the central DBD) and the presence of T0 was found to be 
necessary for full gene activation 4. Even though the region at the N-terminal of the first 
repeat did not seem to be conserved, later on a study done with the protein sequence of 
this region showed that the secondary structure is conserved to some degree and can 
specifically bind T 5. 
 
2 
 
Even though the predominant length of TAL repeats is 34 amino acids, in 
naturally existing TAL effectors, repeats of different sizes exist, and apart from the 
RVD there are polymorphisms observed in different residue positions. In Xanthomonas 
spp. polymorphisms at positions 4 and 32 are common (Figure 1.2), and in addition to 
these there are other amino acid substitutions which are rarely found. The 
polymorphisms in non-RVD domains do not seem to affect the base preference of the 
repeat and their function is not clear. Also, it is not known whether all types of repeats 
of various lengths and different polymorphisms that are found in nature are functional 1. 
 
  
Figure 1.2 Some of the most frequently seen polymorphisms among 2023 TAL 
repeats of 113 known TAL effectors from Xanthomonas spp. Most TAL repeats consist 
of 34aa, the repeat units are generally conserved with the exception of 12th and 13th 
(RVD) along with 4th and 32nd positions, which do not seem to have an effect on base 
preference 1. The base pairs these repeats recognize are shown with the colors indicated 
in Figure 1.1. 
 
The simplicity of the one repeat-one base system  and the independence of these 
repeats from each other in terms of specificity enables targeting any sequence in the 
genome by designing custom arrays of repeats and it enables the construction of 
artificial transcription factors as well as proteins with various functions by fusing a TAL 
protein to other domains 2. 
 
 
 
 
 
3 
 
1.1.2 Crystal Structure of TAL Effector Proteins 
 
The crystallization studies done on TAL effectors unraveled many features of 
TALE proteins at the atomic scale. In 2012, Mak et al. crystallized the DNA binding 
domain of the naturally occurring TAL effector protein PthXo1 from the rice pathogen 
X. oryzae as bound to its DNA target (PDB:3UGM) 5. In the same year Deng et al. 
shown the crystal structure of an artificially engineered TAL effector protein, dHax3 in 
both DNA-free and DNA-bound forms (PDB: 3V6P and 3V6T, for DNA-free and 
DNA-bound structures, respectively) 6. These two studies shed light on many questions 
about the sequence-specific recognition of DNA by the TAL repeat structure.  
 
Crystallographic studies of TALEs showed that the DNA binding domain forms 
a right-handed superhelical assembly wrapped around the B-form DNA helix in a way 
which enables specific repeat-nucleotide interactions (Figure 1.3). An array of TAL 
repeats complete a full helical turn around the DNA, the RVD loops form the inner 
most spiral with a pitch of 60 Å per turn. The consecutive bases of the target site are 
intimately engaged in the major groove and all of the repeats in the DNA-bound 
structure form nearly identical two-helix bundles, reflecting the degree of high sequence 
conservation. The consecutive helices are packed left handedly and the shorter one, 
helix a, spans positions 3 to 11 while the longer and bent one, helix b is made up of 
residues 14 to 33. The two helices are connected by a short loop which contains the 
RVD. The kink in the second helix is generated by a proline at position 27 and it 
appears to be critical for the sequential packaging and association of tandem repeats 
with the DNA double helix 5,6. 
 
In both of the studies, the two hypervariable residues in the RVD loops are 
positioned in close proximity to the sense strand in the DNA major groove and the first 
and the second residue appear to have different biochemical roles. While the sequence-
specific contacts are made exclusively by the 13th residue in each RVD, the 12th residue 
does not directly contact DNA. The first residue in the RVD makes direct hydrogen 
bonds to the backbone carbonyl oxygen of the alanine at position 8 in each repeat 
through its side chain, constraining the RVD containing loop. Ala8 is invariant and 
located at the C-terminal end of helix a in each TAL repeat, and appears to have a 
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critical role in stabilizing the conformation of the RVD loop by binding the 12th residue, 
thus facilitating the sequence recognition for the 13th residue 5,6. 
 
 
Figure 1.3 Crystal structure of the natural TAL Effector protein, PthXo1. a) Side view 
of PthXo1 in its DNA bound form. The protein backbone is indicated in pink and the 
DNA double helix is shown in red. b) Top view of the DNA bound PthXo1  c) Crystal 
structure of a single repeat unit containing an HD RVD, the H residue is shown in red, 
the D residue in green and alpha helices in purple (PDB: 3UGM 5). 
 
All RVDs appear to have different characteristics to bind their corresponding 
bases, but their specificity is determined by the 13th residue. In the HD RVDs, the 
aspartate residue makes van der Waals contacts with the edge of the cytosine base and a 
hydrogen bond to the cytosine N4 atom. The contacts between the cytosine base and the 
charged acidic side chain of Asp13 are both physically and electrostatically specific and 
close out the possibility of binding other bases. In the case of NS, which is a non-
selective RVD that binds all four of the bases, the hydroxyl group of Ser13 donates a 
hydrogen bond to the N7 atom of adenine, which also exists in guanine. Binding of 
cytosine and thymine might require a slightly different conformation of the loop. In the 
case of the NN RVD too, the second asparagine residue is positioned to make a 
hydrogen bond with the N7 nitrogen of the corresponding guanine base. Since the N7 
nitrogen is available in both purines, NN can also bind adenine.  NI RVD which binds 
an adenine base rather specifically demonstrates an exceptional contact pattern. The 
aliphatic side chain of the isoleucine residue was observed to make nonpolar van der 
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Waals contacts to C8 of the adenine purine ring which would normally cause 
desolvation of at least one polar atom in the ring. This might be the reason behind its 
reduced affinity. The contact made between NG and HG repeats and the thymine base is 
also interesting. Instead of making any specific interactions, the placement of Gly at 
position 13 allows sufficient space to contain the 5’ methyl group of thymine. The 
distance between the C of Gly13 and the 5-methyl group of thymine is small (around 
3.4 Å), allowing van der Waals interactions. Substitution of Gly with any other residue 
would likely introduce a steric clash with the 5-methyl group of thymine, explaining the 
specificity of NG and HG binding 5–7. 
 
The PthXo1 structure also revealed two degenerate repeat folds that are at the N-
terminal of the central repeats that appear to cooperate to specify the conserved thymine 
that precedes the targeted sequence by RVDs. Residues 221 to 239 and residues 256 to 
273 in the PthXo1 structure each forms a helix and an adjoining loop that resembles 
helix a and the RVD loop in the repeats of the DNA binding domain. These two N-
terminal regions approach each other near the 5’ thymine base, making a van der Waals 
contact with the methyl group of that base 5. 
 
 
1.1.3 Designing Custom TAL Effector Proteins 
 
Thanks to the simplicity of the DNA recognition code and the modularity of the 
protein, TALEs allow the design of many functional proteins that would modify gene 
sequences and gene expression targeting any site in the genome. In principle, only by 
determining the number and order of the required RVDs, any site can be targeted; and 
by fusing these repeats to different functional domains, TALE proteins can be directed 
to their specific loci to induce the desired modification (Figure 1.4). Fusion of 
regulatory domains to TALE repeats enabled construction of proteins that induce 
activation or repression on the endogenous expression of the targeted genes 8,9. For site 
directed mutagenesis nonspecific nucleases fused to the TALE DNA binding domains 
have been used 10–12. Also, TALEs fused with the catalytic domains of invertase, named 
TALE recombinases, have become another important tool for site-specific modification 
of the genome 13. 
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Figure 1.4 TALE based custom proteins can be used to target DNA. Functional domains 
such as activators, repressors, nucleases and recombinases can be fused to the central 
DNA binding domain of TAL effectors on the C-terminal end for targeted modification 
of genomes. TALE central repeats are color coded according to RVDs as shown in 
Figure 1.1 2. 
 
Assembly of the TALE repeats are generally done with the most common RVDs 
NI, NG, HD and NN which bind adenine, thymine, cytosine and guanine respectively. 
Among these RVDs, NN also recognizes adenine which might be an impediment if 
specific recognition of a target region is desired, because it is possible for the designed 
protein to bind other sites in the genome. For that reason, NK and NH, RVDs that are 
found less common in nature, but more specific in recognizing guanine could be used; 
however, comparison studies have shown that even though these two were more 
specific, the TALE proteins that include these RVDs for guanine recognition had 
significantly lower activities compared to their NN containing counterparts 14,15. 
Therefore, while constructing TALE proteins against targeted loci, both specificities 
and binding efficiencies of the individual RVDs should be taken into account and they 
should be chosen according to the requirements of the experiment.  
 
 
1.1.4 Targeted Genome Modification Using TALENs 
 
 TALE nucleases (TALENs) are generated by the fusion of the DNA binding 
domain of a TALE protein to a nuclease functional domain. Using site specific 
nucleases for genome editing has become a trend in both studies of gene function and 
gene therapy research. Double stranded breaks induced by nucleases can result in gene 
inactivation because of non-specific DNA repair, and desired genome modifications can 
be induced by homology directed repair in specific sites. Before TALENs, zinc finger 
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nucleases (ZFNs) were being used as programmable and sequence specific tools for 
targeting endogenous gene loci and were utilized for therapeutic purposes that had 
proved to be a great success 16. ZFNs were used to directly correct the disease causing 
mutations associated with X-linked severe combined immune deficiency (SCID) using 
homology directed repair 17, to genetically repair Parkinson’s disease-associated 
mutations within the SNCA gene in patient-derived human iPS cells 18; and to knockout 
the CCR5 (C-C chemokine receptor type 5) gene in primary T cells by ZFN induced 
non-homologous end joining (NHEJ) to render these cells resistant to HIV. Since CCR5 
is a co-receptor that takes part in HIV infection, this method holds great potential to 
defeat HIV and currently is being examined under clinical trials 19. 
 
TALENs are second generation genome editing tools. The first genome editing 
tool to be used was ZFN. Among DNA binding motifs, the zinc finger domain is the 
most common type found in eukaryotes. An individual zinc finger consists of 
approximately 30 amino acids in a conserved ββα configuration and several amino acids 
on the surface of the α-helix typically contact 3bp in the major groove of DNA with 
different selectivity levels. After the discovery of a highly conserved linker sequence, 
synthetic arrays that contain more than three zinc finger domains were developed and 
eventually custom zinc-finger proteins that recognize 9-18bp long DNA sequences were 
constructed 20. Generation of a zinc finger module library that contains the domains 
which recognize nearly all of the 64 possible nucleotide triplets led to the modular 
assembly of DNA binding domains that targets unique DNA sequences with relatively 
high specificity. The fusion of this domain to a DNA nuclease made this protein an 
important tool for targeted gene modification. Traditionally targeted gene inactivation, 
replacement, or gene insertion could only be achieved by homologous recombination 
which had too low efficiency in mammalian cells without the induction of double strand 
breaks; however, previously found site-specific nucleases would target multiple sites in 
complex genomes and their cytotoxicity levels were high 21. For that reason, the zinc-
finger motif was fused to the non-sequence-specific DNA cleavage domain of the 
restriction enzyme FokI, which is a type IIS restriction endonuclease that functions as a 
dimer. To induce double strand breaks, ZFNs that target two closely oriented inverted 
half sites should bind each other from their FokI domains at the spacer region in 
between the half sites. Therefore, DNA cleavage is generated only upon the 
heterodimerization of the two nucleases. Using this strategy for targeted genome 
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modification increased the specificity and reduced the off-target activity and cell 
toxicity the other site-specific nucleases induced  16.  
  
Even though ZFNs have been used for modifying the genome of diverse model 
organisms for various purposes, the presence of off-target activity and ZFN-associated 
genotoxicity is still a major issue for therapeutic studies. Crosstalk between the 
individual zinc finger motifs causes each motif to affect the specificity of an adjacent 
motif and some of the domains themselves are able to recognize multiple triplets, 
making design of sequence-specific ZFNs very challenging. The imperfect target-site 
recognition by the zinc-finger DNA binding domains requires many optimization 
experiments before application 22. 
 
 
 
Figure 1.5 TALEN structure for genome editing. TALEs fused to the FokI DNA 
cleavage domain are used as pairs since the FokI enzyme requires dimerization for its 
DNA cleavage activity. Each TALE central repeat domain is designed to target the 
corresponding sequence. Once TALEs bind the DNA, FokI assembles on the spacer to 
cleave this region. TALEN enzymes have a modified structure compared to naturally 
occurring TALE proteins. The NLS is located at the N-terminus; the FokI domain 
(brown) is fused to the C-terminus. Each unit in the central repeat is color coded to 
indicate the RVD-DNA binding code 11,23. 
 
 
Generation of custom transcription activator like effector nucleases (TALENs) 
for targeted genome modification attracted much attention due to the simplicity and 
manipulability of its one RVD - one base targeting mechanism. As in ZFNs, the FokI 
DNA cleavage domain is fused to the DNA binding domain of the TALE protein and it 
functions as a heterodimer, increasing target specificity. The FokI domain is at the C-
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terminal end of the proteins and as the DBD of the second monomer binds the reverse 
strand of the DNA leaving a short distance in between, the FokI domains of the two 
proteins assemble on the spacer region and generate a double strand break (Figure 1.5) 
11.  
 
TALEN technology was successfully used for targeted genome editing in yeasts 
24, C. elegans 25, plants as model organisms or crops 26,27, Drosophila melanogaster 28, 
zebrafish 29, frogs 30, mouse 31,32, rat 33, and livestock 34. With the experiments done so 
far, the TALEN efficiency varies usually from 10 to >50% with an average around 22% 
cells mutated 35,36. In studies that are done to compare TALENs with ZFNs, along with 
the simplicity of its design and assembly, TALENs were found to be significantly more 
mutagenic and efficient 35 while the toxicity caused by off-target cleavage of the 
genome was much less frequent 37, rendering TALENs more preferable over ZFNs.   
 
 
1.1.5 Types of Genome Modification 
 
The basis of targeted genome modification through site-specific nucleases is to 
induce double strand breaks at the targeted site and to trigger cellular repair mechanisms. 
The double stranded break is either repaired by non-homologous end joining (NHEJ) or 
by homologous recombination (HR) in case a homologous donor DNA is supplied 
(Figure 1.6). After TALEN pairs induce a double strand break on the targeted site, 
NHEJ-mediated repair leads to the introduction of small insertions or deletions 
(INDELs) on the targeted site resulting in the disruption of the region, two-thirds of 
which causing frame-shift mutations that would knock-out the gene.  TALENs were 
successfully used to knock out various genes without the introduction of exogenous 
DNA 34. Apart from random mutations, homologous recombination can result in gene 
deletions, gene insertions or gene replacements can be induced at the target site by co-
delivering TALEN pairs with a donor plasmid that has locus-specific homologous arms 
along with the desired sequence. With this method, specific genes can be integrated into 
the genome or an epitope tag can be inserted to label the protein of interest, a defective 
gene can be repaired or a large sequence can be removed from the genome. Along with 
plasmids, linear DNA sequences and single-stranded oligonucleotides can be used as 
effective donors 16. It was also shown that by the transfection of multiple TALEN pairs 
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simultaneously, deletion or inversion of large chromosomal segments were possible. In 
cases where different chromosomes were targeted, translocations could be induced 38. In 
addition, by synchronizing TALEN mediated DNA cleavage of the donor DNA with the 
chromosome, large expression cassettes (~15kb) could be inserted into the genome 
through NHEJ-mediated ligation 39.  
 
 
 
Figure 1.6 TALEN induced genome editing. Genome editing after DSB generation is 
done either by non-homologous end joining (NHEJ) or by homologous recombination 
(HR). a) In the case genome editing using one TALEN pair, NHEJ results in small 
insertions and deletions (INDELs) at the site of the DSBs. HR can be used for gene 
deletion, gene insertion (for example an epitope tag) or gene replacement (for example a 
fluorescent reporter gene such as GFP) depending on the donor template used. b) If two 
TALEN pairs create DSBs on the same chromosome simultaneously, NHEJ mediated 
repair may result in chromosomal deletion or inversion. If DSBs are generated on 
different chromosomes, translocations may occur 2,23. 
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1.1.6 Applications of Genome Editing Using TALENs 
 
Targeted genome modification by TALENs have been used in various model 
organisms. First studies typically used NHEJ-mediated mutagenesis to knock out genes 
or to nullify a phenotype 35,36. TALEN pairs along with double strand donor DNA were 
used to insert expression cassettes into targeted regions in human cells 40 or induce 
specific modifications in the targeted site of zebrafish embryos by homologous 
recombination 41.  Similarly, homology directed repair could successfully be induced 
with single strand oligonucleotide donors that have ~50bp long homology arms leading 
to precise modifications in zebrafish and mouse models 32,42. This method can be used 
for fusion of endogenous genes to sequences encoding epitope tags or fluorescent 
reporter proteins such as GFP to track protein expression, distribution and interaction 
with other proteins (Figure 1.6) 38. Simultaneous transfection of two TALEN pairs 
generated heritable large chromosomal deletions in silkworm 43 and livestock genomes 
34. All of these studies have shown that the TALENs are applicable for many means of 
gene editing. One of the most important approaches of genome modification studies is 
to develop knock-out model organisms and a widely used and successful way to do it is 
the microinjection of in vitro synthesized mRNAs encoding a custom TALEN pair into 
a zygote. With this method, zebrafish, livestock, rat and mouse disease models were 
generated   32–34,41,42,44. 
 
In this study we used TALENs to disrupt two of the transcription factor binding 
sites in the enhancer region of the IL7R gene using NHEJ-mediated INDEL 
mutagenesis. In addition, we introduced two TALEN pairs simultaneously to delete an 
entire intronic region in the same gene. We also used TALENs against the translation 
start site of the GR gene to knock out gene expression and we designed a donor plasmid 
homologous to the same site with a Venus-YFP insert to fuse it with GR.  
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 1.2 Interleukin-7 signaling 
 
 
1.2.1 Interleukin-7 and Interleukin-7 Receptor 
 
Interleukin-7 (IL-7) is a cytokine which plays an essential non-redundant role in 
the development, differentiation and survival of lymphocytes.  IL-7 was first discovered 
in 1988 as a factor that promoted the growth of the murine B cell precursors in a bone 
marrow culture system 45. Then it was shown that injecting mice with IL-7 increased 
both T and B lymphocyte numbers dramatically while the studies with IL-7 and IL-7 
receptor (IL-7R) defective models demonstrated significant reductions in the number of 
lymphocytes 46. These studies and the following ones confirmed IL-7’s role in 
lymphocyte development and proliferation. In addition to these, IL-7 has a role in 
homeostasis of T lymphocytes; as well as in the early and late stages of the T cell 
development, it promotes cell survival in naïve and memory T cells of the peripheral 
immune system 47. 
 
The human IL-7 gene is 72kb long and it is located on chromosome 8, encoding 
a protein of 20kD; whereas murine IL-7 gene is 41 kb long, located on chromosome 3 
and encodes a protein of 18kD. Due to post-translational glycosylation, the active form 
of human IL-7 is 25kD in size and it is a single chain protein consisting of four α helices 
with a hydrophobic core. IL-7 is produced by non-lymphoid cells in lymphoid organs 
such as bone marrow stromal cells and epithelial cells of the thymus; and in humans it is 
also expressed in epithelial cells of the skin and intestine 48,49. In the thymus, 
lymphocytes in the earliest stages require IL-7 for survival, proliferation and 
rearrangement of the TCR (T cell receptor) genes. Mature T cells after leaving the 
thymus also require IL-7 for survival and homeostatic proliferation. While murine B 
lymphocytes also require IL-7 for development, human B cells do not 49. 
 
IL-7 signals lymphocytes by binding to its specific receptor, IL-7R.  The 
receptor is expressed on the membrane and it is composed of a heterodimer of two 
transmembrane proteins. The α chain is specific (IL-7Rα, also known as CD127) and it 
is dimerized by a common cytokine receptor γ chain (γc), which is also shared by the 
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receptors of IL-2, IL-4, IL-9 and IL-15. Each of these chains is expressed on the cell 
surface independently of each other, although the two chains could pre-associate. The 
subunits as momomers or as homodimers are not sufficient to bind IL-7; both of these 
subunits are essential for efficient signaling 49.  
 
The human IL-7Rα gene is mapped on chromosome 5 with a size of ~20kb 
while the murine IL-7Rα gene is on chromosome 15 with a size of ~22kb. Both human 
and murine genes contain eight exons and seven introns. IL-7R is composed of 439 
amino acids in its mature form with a molecular weight of 49.5 kD. IL-7Rα is mainly 
expressed in cells of the lymphoid lineage, such as T lymphocytes, progenitor B-
lymphocytes, NK cells, dentritic precursors, and bone marrow-derived macrophages. 
Although their role in non-lymphoid cells is not well known, IL-7Rα is also expressed 
in normal human intestinal epithelial cells, endothelial cells, colorectal cancer cells, 
breast cancer cells and some other malignant cell lines 49,50. 
 
 
1.2.2 IL-7 Receptor Signaling Pathways 
 
The components of the IL-7 receptor, IL-7Rα chain and common γ chain 
dimerize upon IL-7 extracellular cytokine binding. Dimerization activates kinases 
bound to γc and IL-7Rα on the intracellular domains, JAK3 and JAK1. The 
phosphorylation of IL-7Rα intracellular domain by JAK1 triggers recruitment of PI3K 
and STAT proteins. JAK protein phosphorylates STAT proteins, which results in their 
dimerization and translocation to cell nucleus in order to bind transcription activation 
sites of genes such as Bcl-2, SOCS-1, cyclinD1 and c-myc to promote cell 
differentiation and survival. Also, recruitment of PI3K to the IL-7Rα intracellular 
domain activates this kinase and results in phosphorylation of the Akt, which promotes 
cell survival by causing the degradation of pro-apoptotic proteins such as Bad and Bax 
(Figure 1.7) 51. 
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Figure 1.7 The IL-7 receptor signaling pathway 51. 
 
 
1.2.3 Importance of the IL-7R Signaling for Lymphopoiesis 
 
B cell development mainly takes place in the bone marrow and it can be 
subdivided into various stages depending on the expression of different intracellular and 
cell surface markers, the rearrangement status of the heavy and light immunoglobulin 
chains, and their cell cycle status 52. The most important stages of B cell development in 
the bone marrow and their IL-7R expression pattern are shown in Figure 1.8.  
 
The block of transition from the pro-B cell to pre-B cell stages in IL-7R 
deficient mice indicates that IL-7 signaling has an essential role in B lymphocyte 
development 53. Later on it was reported that IL-7Rα regulates access to 
immunoglobulin heavy chain coding gene segments during somatic recombination, 
which is a critical step for the diversity of antibodies 54. In the pre-B cell stage, IL-7R 
signaling is stopped before the rearrangement of the light chain gene locus by the 
upregulation of the IRF-4 transcription factor 55. The transition from the pro-B stages to 
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later ones is regulated by transcription factors such as EBF, which is upregulated by IL-
7R signaling 56. 
 
Figure 1.8 IL-7R expression by lymphocytes 57. B lymphocytes of the bone marrow and 
T lymphocytes of the thymus express IL-7R on the cell surface at different stages of 
development. The expression of IL-7R is dynamically regulated during development. 
 
 
IL-7 signaling is essential for T lymphocytes throughout their life cycle; it has 
roles in T cell maturation, differentiation and mature T cell survival in peripheral 
lymphoid tissues. IL-7R expression is strictly regulated over the course of T cell 
development. It is expressed on double-negative thymocytes, its expression is turned off 
in the double positive stage and it is re-expressed in single-positive stage (Figure 1.8). 
IL-7 signaling first occurs at the double negative (DN) stage which can be subdivided 
into four groups from DN1 to DN4, determined by the surface expression of CD44 and 
CD25. IL-7Rα expression starts at the DN2 stage and the signaling occurs at the DN3 
stage, where TCRβ selection of the DN thymocytes occurs. IL-7R signaling is critical 
for the survival and proliferation of these selected cells. IL-7 deficient cells are 
normally found to be developmentally arrested at the DN3 stage and overexpression of 
anti-apoptotic molecules such as Bcl-2 or deletion of pro-apoptotic factors such as Bim 
and Bax can compensate for the lack of IL-7 signaling which shows that in this stage 
IL-7 is responsible of providing survival signals (reviewed in 58). IL-7R expression is 
downregulated in the DN4 stage and terminated in immature CD4+CD8+ double 
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positive (DP) thymocytes. This termination is also important since IL-7 signaling 
inhibits expression of the transcription factors TCF-1 and LEF-1, which are essential for 
DP cell differentiation 59. DP thymocytes are metabolically inactive and pre-
programmed for cell death. As a result of positive selection, post DP intermediate cells 
(CD4+CD8low) start to express IL-7R again, and CD8 coreceptor transcription is 
downregulated. Persisting TCR signaling differentiates intermediate cells into CD4 SP 
cells, whereas intermediate cells that no longer receive TCR signals differentiate into 
CD8 SP cells due to IL-7 signaling 60.  
 
IL-7 is also a central regulator of peripheral T-cell homeostasis and survival for 
both naive and memory CD4 and CD8 T cells. IL-7R is only down-regulated upon T 
cell activation and memory cell differentiation when other γ chain cytokines such as IL-
2 and IL-15 take over survival signaling. After differentiation is complete IL-7R is re-
expressed in memory T cells 61.  
 
 
1.2.4 Regulation of the IL-7R alpha Gene 
 
During the development of both B and T lymphocytes IL-7Rα is expressed 
differentially and its expression is strictly regulated throughout their life cycle. The 
expression in different stages is controlled by various transcription factors. 
Bioinformatically identified transcription factor binding sites on the IL-7Rα gene locus 
are shown in Figure 1.9.   
 
 
Figure 1.9 IL-7R gene locus with various transcription factor binding sites. 
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In the gene locus there are three evolutionarily conserved regions (ECR); one in 
between the second and the third exons, one in the promoter region, and one in the 
upstream region. In the IL-7Rα promoter there is a GGAA motif region which is a 
binding site for the PU.1 transcription factor. PU.1 is an ETS family transcription factor 
and was demonstrated to take role in IL-7R expression of developing B cells 62. In T 
cells this site is bound by GGAA binding protein (GABP), which is also an ETS family 
transcription factor. In the absence of PU.1 GABP can promote IL-7R expression in 
commited B cells too, but not in early B cell progenitors 63. Another transcription factor 
that binds the IL-7R promoter region is Runx1. The deficiency of Runx1 in CD4 T cells 
was shown to result in reduced IL-7R expression levels and a shorter survival period. 
This indicated that Runx1 transcription factor was necessary for the positive selection 
and maturation of CD4 SP cells by IL-7 mediated survival signaling 64.  
 
About 3 kb upstream of the IL-7Rα transcription initiation site there is another 
evolutionarily conserved region which contains the binding sites for transcription 
factors Gata, NFkB, glucocorticoid receptor (GR) and Foxo. GATA-3 is a zinc-finger 
transcription factor that is essential for the generation of the earliest T cell progenitors 
and it was shown that GATA-3 expression was required for the generation of IL-7R 
positive thymus derived NK cells while bone marrow derived NK cells could develop in 
its absence 65. Foxo1 is a transcription factor that has various roles in cell regulation. In 
T cells it was shown that Foxo1 deficiency resulted in severe defect in IL-7Rα 
expression. Other factors that have roles in the regulation of naïve T cell homeostasis 
and life-span were also shown to be affected by Foxo1 66. NFkB, which is another 
transcription factor that has a binding site in the IL-7R enhancer region, is an important 
regulator for the activation, proliferation and survival of thymocytes. It was recently 
shown that IL-7 stimulation on NFkB deficient T cells did not enhance their viability 
and those cells appeared to have reduced IL-7R levels both for the protein and mRNA; 
demonstrating the role of NFkB in the regulation of IL-7R expression 67.  
 
1.2.4.1 Notch Transcription Factor 
 
The Notch pathway regulates cell proliferation, cell fate, differentiation, and cell 
death in all metazoans. Notch is a cell-surface receptor that sends short-range signals by 
interacting with transmembrane ligands such as Delta (Delta-like in humans) and 
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Serrate (Jagged in humans) on neighboring cells. Upon ligand binding, the ligand-
receptor complex unfolds a juxtamembrane negative control region which allows access 
of ADAM10 protease to site 2 (S2) to cleave the Notch extracellular domain. Then γ-
secretase induces the second cleavage at site 3 (S3) to release the Notch intracellular 
domain (NICD) from the membrane. NICD then travels to nucleus to bind 
transcriptional complexes containing a DNA binding protein CBF1/RBPjK/Su(H)/Lag1 
(CSL) and its co-activator Mastermind-like (MAML) to regulate target gene expression 
(Figure 1.10) 68.   
 
 
Figure 1.10 Notch signaling 68. The Notch intracellular domain (NICD) is released from 
the membrane upon ligand binding induced cleavage of the Notch receptor on the 
plasma membrane. Cleaved NICD translocates into the nucleus, binds a preexisting 
CSL (RBP-Jk) transcription factor complex, helps recruit of the adaptor protein 
Mastermind-like (MAML) and promotes transcriptional activation. 
 
The studies done with mice have shown that the loss of Notch1 could cause a 
reduction in thymus size and deficiency in thymocyte development. In addition, while 
Notch1-deficient bone marrow can contribute to the development of all hematopoietic 
cells normally, T cell development was blocked at an early stage, before the expression 
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of T cell lineage markers 69. Also in another study Notch1 was found to bind CSL 
binding motif (RBP-Jk) IL-7R in vivo and in early thymic precursors Notch1 ectopic 
expression consistently resulted in the generation of DP thymocytes with up-regulated 
IL-7R while defective Notch1 signaling impaired their IL-7R expression, resulting in a 
developmental arrest that could be rescued by ectopic expression of IL-7R 70. These 
findings suggest that Notch1 has an essential and selective role in T cell maturation. 
 
 
 
1.2.4.2 Glucocorticoid Receptor (GR) 
 
Activated lymphocytes or macrophages secrete inflammatory cytokines such as 
TNF-α and IL-1β to activate components of the inflammatory system. As a result of an 
endocrine feedback loop, the release of these cytokines subsequently stimulate the cells 
of the adrenal cortex and they secrete glucocorticoids (GC) to induce anti-inflammatory 
effects on immune cells through interruption of proinflammatory cytokine-mediated 
signaling pathways or by apoptosis 71. Along with these, GCs are shown to have various 
effects on the growth, differentiation and function of lymphocytes 72.  
 
Due to their lipophilic nature, GCs can readily diffuse through the plasma 
membrane and bind to the glucocorticoid receptor (GR) in the cytoplasm. GR in its 
inactive form is in a complex consisting of heat shock proteins (such as hsp90) and a 
low weight molecular protein p23. GR is activated upon binding its ligand, and it 
dissociates from its chaperone proteins. Once released, its nuclear localization signals 
become exposed and it translocates to the nucleus to stimulate or inhibit the activation 
of its target genes (Figure 1.12). Apart from binding the DNA directly, GR can also 
induce transcription regulation by binding other factors 71. GR was shown to bind the 
IL-7Rα upstream enhancer region and activate the IL-7R expression in mouse early 
stage thymocytes 73. Also, treatment with dexamethasone, which is a synthetic 
glucocorticoid, was shown to increase IL-7Rα expression at both the mRNA and protein 
levels in mouse and human cells 74,75.   
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Figure 1.12 Glucocorticoid receptor signaling. Inactive GR is bound by the chaperones 
Hsp90 and p23 in the cytoplasm until encountering a ligand. Glucocorticoids are 
hydrophobic and freely diffuse into the cell, and upon binding GR it causes its 
activation. Active GR dissociates from its chaperones, is phosphorylated and 
translocates into the nucleus to bind DNA. GR can activate genes that have 
glucocorticoid response elements (GRE) in their promoter and inhibit genes that have 
negative GRE (nGRE) 71.  
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2.  AIM OF THE STUDY 
 
 
Transcription activator-like effector (TALE) proteins from the plant pathogen 
Xanthomonas consist of highly conserved repeat units in their central DNA binding 
domain (DBD). Binding specificity of the each repeat is determined by the polymorphic 
amino acid residues at positions 12 and 13, named as repeat variable di-residues 
(RVDs). The simplicity of one RVD - one base code and the modular structure of the 
DBD enable the assembly of proteins that can target any site in the genome with high 
specificity and various functions. TALE nucleases (TALENs), which are generated by 
the fusion of the non-sequence specific DNA cleavage domain of FokI to the TALE 
DNA binding domain, have become an important tool for targeted gene modification. 
TALENs induce double strand breaks (DSBs) at the targeted site and cellular repair of 
the disruption occurs either by non-homologous end joining (NHEJ) or by homologous 
recombination (HR) which results in site directed mutagenesis. We used TALENs to 
modify the genome of mouse cells. 
  
In the first part of the study, we targeted the IL-7Rα gene and aimed to mutate 
two of the transcription factor binding sites in the upstream enhancer region to observe 
the effects of these mutations on IL-7R expression. We also targeted the exon 2 and 
exon 3 of IL-7R to delete a transcriptional control element in intron 2. We designed and 
constructed TALEN pairs targeting the binding sites of glucocorticoid receptor (GR) 
and Notch transcription factors, along with the exon targeting ones and expressed them 
in the murine RLM11 cells. We used the restriction fragment length polymorphism 
(RFLP) assay and DNA sequencing to detect mutations and we monitored IL-7R 
expression by flow cytometry. In the second part of the study we targeted the gene 
encoding the GR transcription factor and designed a TALEN pair against the translation 
start site to knockout the gene. Also, we designed a donor plasmid homologous to the 
same site with a Venus-YFP gene insertion to fuse endogenous GR with Venus through 
homologous recombination. With the knockout experiment, we aimed to observe the 
effects of GR gene deficiency and with homologous recombination we aimed to 
generate a model that would enable tracking GR activities within the cell.   
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3.  MATERIALS AND METHODS 
 
 
3.1 Materials 
 
3.1.1 Chemicals 
All the chemicals used in this project are listed in the Appendix A. 
 
3.1.2 Equipment 
All the equipment used in this project are listed in the Appendix B. 
  
3.1.3 Buffers and Solutions 
Standard buffers and solutions used in this project were prepared according to 
the protocols in Sambrook et al., 2001. 
 
Calcium Chloride (CaCl2) solution: 60 mM CaCl2, 15% glycerol and 10mM 
PIPES at pH 7.00 were mixed and the solution was filter-sterilized and stored at 4°C for 
competent cell preparation. 
 
5X Tris-Borate-EDTA (TBE) Buffer: 54 g Tris base, 27.5 g Boric acid and 
20mL of 0.5 M EDTA at pH 8.00 were dissolved in 1L of dH2O and stored at RT. 
 
1% (w/v) Agarose gel: 1 g of agarose was dissolved in 100 mL of 0.5X TBE 
buffer by heating in a microwave oven. 0.001 % (v/v) of ethidium bromide was added 
to the solution for visualization of nucleic acids. 
 
23 
 
Phosphate-buffered saline (PBS): 1 tablet of PBS was dissolved in 200 mL of 
dH2O. The solution was filter-sterilized for use in mammalian cell culture and stored at 
4°C. 
Polyethylenimine (PEI) (1μg/μL): 50 mg PEI was dissolved in 50 mL dH2O 
that has been heated to ~80°C and cooled to room temperature. After neutralizing to pH 
7.00, the solution was filter-sterilized, aliquoted and stored at -20°C. 
 
FACS buffer: 0.5 g Bovine serum albumin (BSA) and 0.5 g sodium azide were 
dissolved in 500 mL 1X HBSS and stored at 4°C. 
 
3.1.4 Growth Media 
 
3.1.4.1 Bacterial growth media 
 
Liquid media: 20 g Luria-Broth (LB) was dissolved in 1 L of dH2O and 
autoclaved at 121°C for 15 min. For selection, ampicillin with a final concentration of 
100 μg/mL and spectinomycin with a final concentration of 50μg/mL were added to 
liquid medium after autoclave. 
 
Solid media: 35 g LB agar was dissolved in 1 L of dH2O and autoclaved at 
121°C for 15 min. For selection, antibiotics with previously indicated concentrations 
were added to autoclaved medium after cooling down to 50°C. Autoclaved and 
antibiotic added medium was poured onto sterile Petri dishes. Solid agar plates were 
stored at 4°C. 
 
3.1.4.2 Mammalian cell culture growth media 
 
The adherent cell line HCT116 was grown in DMEM cell culture medium that 
was supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-
glutamine, 100 unit/mL penicillin and 100 unit/mL streptomycin. 
 
The suspension cell line RLM11 was grown in RPMI 1640 cell culture medium 
that was supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-
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Glutamine, 100 unit/mL, 100 unit/mL streptomycin, non-essential amino acids, vitamin 
and 50 μM 2-mercaptoethanol. 
Both adherent and suspension cell lines were frozen in fetal bovine serum (FBS) 
containing DMSO at a final concentration of 10% (v/v). Freezing medium was stored at 
4°C. 
 
3.1.5 Cell Types 
 
E. coli DH-5α competent cells were used for bacterial transformation of 
plasmids. RLM11, a radiation-induced BALB/c murine CD4 single positive thymoma T 
cell line, was used for transfection and analysis of IL7R expression level with FACS 76. 
HCT116, a human colonic carcinoma cell line that is generally used for tumorigenicity 
studies, was the only adherent cell line in this study and was used for GR TALEN 
project.  
 
3.1.6 Commercial Molecular Biology Kits 
 
• QIAGEN Plasmid Midi Kit, 12145, QIAGEN, Germany 
• QIAquick Gel Extraction Kit, 28704, QIAGEN, Germany 
• GenElute Mammalian Genomic DNA Miniprep Kit, G1N350, SIGMA, 
Germany 
• GenElute PCR Clean-Up Kit, NA1020, SIGMA, Germany 
• CloneJETTM PCR Cloning Kit, K1232, Thermo Fisher Scientific. 
• InsTAclone PCR Cloning Kit, K1214, Thermo Fisher Scientific 
• Gibson Assembly® Master Mix, New England BioLabs, UK 
 
3.1.7 Enzymes 
 
All enzymes and their corresponding buffers used in this project are from NEB 
and Fermentas. 
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 3.1.8 Vectors and Primers 
 
Vectors and primers used in this project are listed in Table 3.1 and Table 3.2. 
 
Vector Name Purpose Bacterial Resistance 
pcDNA-GFP Transfection efficiency control Ampicillin 
pUC19 Transformation efficiency control Ampicillin 
pHD1-pHD10 
pNG1-pNG10 
pNH1-pNH10 
pNN1-pNN10 
pNI1-pNI10 
 
Module plasmids for 
TALE / TALEN construction 
 
 
Tetracycline 
 
pLR-HD 
pLR-NG 
pLR-NH 
pLR-NN 
pLR-NI 
 
Last repeat plasmids for 
TALE / TALEN construction 
 
 
Tetracycline 
 
pFUS_A 
pFUS_B1- pFUSB10 
Array plasmids for 
TALE / TALEN construction 
Spectinomycin 
pC-Goldy TALEN Backbone plasmid for 
TALEN construction 
Ampicillin 
 
pJET1.2/blunt Cloning of PCR products Ampicillin 
pTZ57R/T Cloning of PCR products Ampicillin 
hAAVS-SA2A-1 Donor plasmid for Puromycin 
resistance gene 
Ampicillin 
mVenus-C1 Donor plasmid for Venus-YFP gene Kanamycin 
Table 3.1 List of vectors used in this project 
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Primer Name Sequence Purpose 
 
Notch for 
BamHI 
 
ATAGGATCCATTGAAACCATAACCACCCTC 
 
Notch TALEN 
Target site 
amplification 
 
Notch rev  
Bgl2 
 
GCGAGATCTCCCTTCTCTCTAATTCTGTT 
 
Notch TALEN 
target site 
amplification 
 
Kpl11 For 
 
CCAAGGAATAAACCCAAGGA 
 
IL7R upstream 
region 
amplification 
 
Kpl12 Rev 
 
AGAAGCACGCTTGTATGTGC 
 
IL7R upstream 
region 
amplification 
 
hGRTalenFwd 
 
AGCTTATGATGTTTTCCCCCCGTTTTTG 
hGR TALEN 
target site 
amplification 
 
hGRTalenRev 
 
AGTCCATCACATCTCCCCTCTCCT 
hGR TALEN 
target site 
amplification 
 
nfkb TALEN 
for 
 
CTTCCCGCACTCTATTTAGAT 
IL7R-GR 
TALEN target 
site amplification 
 
nfkb TALEN 
rev 
 
CTTTCATGGGCTATCACTCC 
IL7R-GR 
TALEN target 
site amplification 
 
Int2R1 Fwd 
 
CCTTCATGTCTGCCACTCAA 
IL7R Exon 2 
TALEN target 
site amplification 
 
Int2R1 Rev 
 
CATATTTGAAATTCCAGATTAGCTGT 
IL7R Exon 2 
TALEN target 
site amplification 
 
Int2R2 Fwd 
 
 
TGGGGCTCTTTTACGAGTG 
IL7R Exon 3 
TALEN target 
site amplification 
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 Int2R2 Rev 
 
 
GCAAAAATAGTTGCTCATGTTTATT 
IL7R Exon 3 
TALEN target 
site amplification 
 
pCR8_F1 
 
TTGATGCCTGGCAGTTCCCT 
Colony PCR of 
Golden GATE 
reaction #1 
 
pCR8_R1 
 
CGAACCGAACAGGCTTATGT 
Colony PCR of 
Golden GATE 
reaction #1 
 
TAL_F1 
 
TTGGCGTCGGCAAACAGTGG 
 
Colony PCR of 
Golden GATE 
reaction #2 
 
TAL_R2 
 
GGCGACGAGGTGGTCGTTGG 
 
Colony PCR of 
Golden GATE 
reaction #2 
 
SeqTALEN_5-1 
 
CATCGCGCAATGCACTGAC 
Sequencing of 
final 
TALEN construct 
pJET1.2 
forward 
sequencing 
primer 
 
CGACTCACTATAGGGAGAGCGCC 
Colony PCR and 
sequencing of 
cloned PCR 
products 
 
pJET1.2 reverse 
sequencing 
primer 
 
TTCTTGTAGCTAAAAGGTACCGTC 
 
Colony PCR and 
sequencing of 
cloned PCR 
products 
 
hGRLeftArm 
Fwd 
 
TGGCTAGCGTCTGTCGGAAGATAAGCAGA
TCAGCATTGTTTA 
hGR homologous 
recombination 
donor construct 
 
hGRLeftArm 
Rev 
 
CAGTGAATATCAACTACAAAACAAAAAAC
AAAAACGGG 
hGR homologous 
recombination 
donor construct 
 
hgrPuro 
Fwd 
 
TTGTAGTTGATATTCACTGATGACCGAGTA
CAAGCCCACGGTGC 
hGR homologous 
recombination 
donor construct 
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 hgrPuro_P2A 
Rev 
 
ACGTCTCCTGCTTGCTTTAACAGAGAGAAG
TTCGTGGCGGCACCGGGCTTGCGGGTC 
hGR homologous 
recombination 
donor construct 
 
hgrP2A_Venus 
fwd 
TAAAGCAAGCAGGAGACGTGGAAGAAAAC
CCCGGTCCCATGGTGAGCAAGGGCGAGGA
GCT 
hGR homologous 
recombination 
donor construct 
 
hgrVenus 
Rev 
 
AGCTCGAGATCTGAGTCCGGACTTGTACAG 
hGR homologous 
recombination 
donor construct 
 
hGRRightArm 
Fwd 
 
CTCAGATCTCGAGCTATGGACTCCAAAGAA
TCATTAACTCCTGGTAGAG 
hGR homologous 
recombination 
donor construct 
 
hGRRightArm 
Rev 
 
GTGGATCCGACTCCAAATCCTGCAAAATGT
CAAAGGTGC 
hGR homologous 
recombination 
donor construct 
Table 3.2 List of primers used in this project 
 
3.1.9 DNA Molecular Weight Marker 
DNA molecular weight marker used in this project is given in Appendix C. 
 
3.1.10 DNA sequencing 
DNA sequencing was commercially performed by McLab, CA, USA. 
(http://www.mclab.com/home.php) 
 
 
3.1.11 Software and Computer Based Programs 
 
The software and computer based programs used in this project: 
Program Name Website/ Company Purpose 
CLC 
Main Workbench 
6.1.1 
 
http://www.clcbio.com/ 
Primer design, molecular 
cloning, sequence data 
management 
FlowJo 7.6.5 http://www.flowjo.com/ FACS data analysis 
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TAL Effector 
Nucleotide 
Targeter 2.0 
 
https://tale-nt.cac.cornell.edu/ 
 
 
TALE / TALEN 
design tool 
Quantity One Bio – Rad Gel image analysis 
Visual Molecular 
Dynamics 
(VMD) 
 
http://www.ks.uiuc.edu/Research/vmd/ 
Crystal structure 
display and 
analysis 
Table 3.3 List of software and computer based programs used in this study 
 
 
 
3.2 Methods 
 
 
3.2.1 Bacterial Cell Culture 
 
3.2.1.1 Bacterial culture growth 
 
E.coli DH5α bacterial cells were grown overnight (~16 h) at 37°C shaking at 
250 rpm in Luria Broth (LB). Bacterial cells were either spread or streaked on LB Agar 
plates to obtain single colonies and grown overnight (~16 h) at 37°C. Antibiotics were 
added to growth media depending on the application. For long-term storage of bacterial 
cells, glycerol was added to the overnight grown culture to a final concentration of 15% 
in 1 mL. Bacterial glycerol stocks were stored at -80°C. 
 
3.2.1.2 Competent cell preparation and transformation 
 
E. coli DH5α competent cells were prepared using stock of previously prepared 
competent cells. 50μL from previously prepared competent cells were grown in 50 mL 
LB without selective antibiotic overnight at 37°C shaking at 250 rpm. Next day, 4 mL 
from the overnight culture was diluted within 400 mL LB and incubated under same 
growth conditions until the OD590 reaches to 0.375. Then, previously prepared ice-cold 
CaCl2 solution was used for resuspension of bacterial cell pellet after successive 
centrifugation steps and for final preparation. 200μL aliquots of competent cells 
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prepared were frozen immediately in liquid nitrogen and then stored at -80°C. 
Competency of prepared cells was tested by transforming varying concentrations of 
pUC19 plasmid. 
 
For transformation of competent cells, CaCl2 treated chemically competent 
bacterial cells were taken from -80°C and ~100 pg of plasmid DNA was added before 
cells were completely thawed. After 30 min of incubation on ice, the cells were 
heatshocked at 42°C for 90 seconds and transferred back to ice rapidly to chill for 60 
seconds. 800μL of sterile LB without antibiotics added and cultures were incubated for 
45 minutes at 37°C for recovery of cells and expression of antibiotic resistance gene 
encoded by the plasmid. Transformed cells were spread onto LB agar plates containing 
appropriate antibiotic for selection using sterile glass beads. Then, the plates were 
incubated overnight at 37°C. 
 
3.2.1.3 Plasmid DNA isolation 
 
Plasmid DNA isolation was performed either by the alkaline lysis protocol or by 
QIAGEN Plasmid Midi Kits. For plasmid isolation, either a single colony of E.coli from 
LB agar plates or a stab of the glycerol stock was grown overnight at 37°C shaking at 
250 rpm in liquid medium containing selective antibiotics with appropriate 
concentrations. The concentration and purity of kit-isolated plasmid DNA were 
determined using Nanodrop. 
 
 
 
3.2.2 Vector Construction 
 
3.2.2.1 The General Methods Used in Vector Construction 
 
Restriction Enzyme Digestion: Digestion reactions containing template DNA, 
enzyme and its compatible buffer were incubated at the optimum temperature of the 
enzyme used for 2 hours. ~ 300 ng of template DNA was used for diagnostic digestions 
whereas the amount of template DNA used for gel extraction and cloning purposes was 
at least 1 μg. 
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 Agarose Gel Electrophoresis and Gel Extraction: Agarose gels to observe DNA 
samples and digestion products were prepared in varying concentrations from 1% to 2% 
depending on the size of DNA fragments to be separated. Agarose gel was prepared by 
dissolving an appropriate amount of agarose powder in 0.5X TBE, heating for 3-5 min 
in a microwave. After cooling-down of the solution to room temperature, ethidium 
bromide was added at a final concentration of 0.001% (v/v) and the gel was poured onto 
the gel apparatus for solidification. 0.5X TBE was also used as running buffer. DNA 
samples were mixed with 6X DNA loading dye before loading to the gel.  
Electrophoresis was performed at 100-135 V for 45-75 minutes and the bands were 
observed under UV light. Gel extraction of DNA samples was performed using a 
QIAGEN Gel Extraction Kit. 
 
Dephosphorylation of Vector Ends: 5’ phosphate groups of linearized vector 
DNA were dephosphorylated using Calf Intestinal Alkaline Phosphatase (CIAP) prior to 
insert ligation, to prevent vector re-ligation. 
 
Ligation: Ligation was performed using T4 DNA Ligase (Fermentas), in 1:3 and 
1:6 molar vector to insert ratio using 100ng vector. In addition, ligation reaction mixture 
without insert was prepared as negative control for each ligation. The ligation reaction 
was incubated at 16°C for 16 hours in a final volume of 20μL. Then, half of the ligation 
mixture was transformed into chemically competent bacteria. 
 
 
3.2.2.2 Vector Construction for Homologous Recombination  
 
 Homologous sites to the targeted region as well as insertion sites that were 
obtained from other plasmids were separately PCR amplified before being fused with 
other PCR products and cloned into their final vector. In order to fuse PCR products 
with each other in the desired order, primers were designed to have homologous 
overhangs at their 5’ ends. After PCR, the correct bands were gel extracted and purified 
from their respective primers; and two or more of these PCR amplicons were used as a 
template in another polymerase chain reaction. In the second PCR amplification with 
multiple templates only the primers in the 5’ and 3’ end of the first two PCR amplicons 
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were used. Because such reactions often generate more than one band, the correct band 
was gel extracted again before further use. The primers at the either end had restriction 
enzyme cut sites instead of a homologous overhang to enable restriction digestion and 
ligation of the final product into a destination vector.  
 
This method was used to fuse exon 2 and exon 3 of IL7R gene to use it as a 
donor 77 and also to construct hGR gene homologous plasmid with Venus-YFP and 
puromycin resistance insertions . The strategies used for these are summarized in Figure 
3.1 and Figure 3.2 in the respective order. The PCR conditions for the hGR donor 
plasmid construction are given in Table 3.4, Table 3.5 and Table 3.6. After obtaining 
the desired construct the gel extracted DNA was either digested on both ends and 
cloned into a plasmid that had the same restriction enzyme cut sites or it was cloned into 
the pJET1.2/blunt plasmid without any digestion using the CloneJETTM PCR Cloning 
Kit (Thermo Scientific).  
 
 
 
 
Figure 3.1 The strategy for fusion of exon 2 and exon 3 of IL7R gene. 
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Figure 3.2 The strategy for construction of puromycin resistance and Venus-YFP 
inserted hGR gene homologous plasmid. 
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 Component   Amount 
Template genomic DNA  
or template Plasmid/Vector (10ng/μl) 
 
1.0μL 
5X Phusion high fidelity buffer 5.0μL 
10mM dNTP each 0.4μL 
Forward primer (10mM) 1.0μL 
Reverse primer (10mM) 1.0μL 
Phusion Hot Start II DNA polymerase (2U/μl) 0.2μL 
dH2O 16.4μL 
Total 25μL 
Table 3.4 The components and the amounts they were used for separate PCR 
reactions that were done in hGR donor plasmid construction.  
PCR was performed according to the following cycle: 
For Left Arm and Right Arm: 
98°C/4 min + 30X (98°C/30 s + 62°C/30 s + 72°C/60 s) + 72°C/10 min  
For Venus: 
98°C/4 min + 30X (98°C/30 s + 63°C/30 s + 72°C/60 s) + 72°C/10 min 
For Puromycin resistance:  
98°C/4 min + 30X (98°C/30 s + 72°C/60 s) + 72°C/10 min (2-step) 
 
 Component   Amount 
Gel extracted PCR product (10ng/μl) 1.0μL each 
5X Phusion high fidelity buffer 5.0μL 
10mM dNTP each 0.5μL 
Forward primer (10mM) 1.0μL 
Reverse primer (10mM) 1.0μL 
Phusion Hot Start II DNA polymerase (2U/μl) 0.2μL 
dH2O 15.3μL 
Total 25μL 
Table 3.5 Optimized PCR conditions for Venus-Right Arm fusion. 
The PCR was performed according to following cycle:  
98°C/4 min + 30X (98°C/30 s + 55°C/30 s + 72°C/2min) + 72°C/10 min 
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 Component   Amount 
Gel extracted PCR product (10ng/μl) 1.0μL each 
5X Phusion high fidelity buffer 5.0μL 
10mM dNTP each 0.5μL 
Forward primer (10mM) 2.0μL 
Reverse primer (10mM) 2.0μL 
Phusion Hot Start II DNA polymerase (2U/μl) 0.2μL 
dH2O 13.3μL 
Total 25μL 
Table 3.6 Optimized PCR conditions for Left Arm - Puromycin resistance gene fusion.  
PCR was performed according to following cycle: 
98°C/4 min + 31X (98°C/30 s + 50°C/30 s + 72°C/2min) + 72°C/10 min 
 
 
Gibson Assembly: Another approach for fusing PCR products that have 
homologous ends is Gibson Assembly (NEB). In the Gibson Assembly Master Mix 
there are 5’ exonuclease, DNA polymerase and DNA ligase that can function at the 
same temperature. After 5’ exonuclease cleaves a portion of the DNA single stranded 
flanks can anneal with their complementary sequence in another PCR product; DNA 
polymerase fills in the remaining gaps while DNA ligase seals the nicks. In this project 
after left homologous arm of hGR gene got fused to puromycin resistance gene and the 
right homologous arm got fused to Venus-YFP via conventional PCR methods, the final 
product that combines all four of them was done using Gibson Assembly Master Mix; 
following the instructions in the kit. Figure 3.3 explains Gibson Assembly’s working 
principle.  
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Figure 3.3 Gibson Assembly working principle for PCR products with homologous 
ends. 
 
3.2.3 Construction of TALEN Expression Vectors 
 
3.2.3.1 Identification TALEN target sites 
 
The software used for design of transcription activator like effectors (TALE) and 
transcription activator like effector nucleases (TALEN) is available for use as an online 
tool (TAL Effector Targeter and TALEN Targeter (old version with design guidelines), 
TALE-NT; https://tale-nt.cac.cornell.edu/). DNA sequence entered is scanned for 
potential TALEN recognition sites based on either preset design guidelines defined by 
four different articles or user-provided spacer and RVD lengths. The software gives 
coordinates and sequences of recognition sites for right and left TALEN monomers and 
the spacer sequence. In addition, RVD sequences necessary for construction of custom 
TALENs were also provided as software output. Binding sites of TALEN pair and 
spacer sequences are given in Table 3.7. 
 
 
 
 
 
37 
 
 
Left TALEN binding 
sequence 
Spacer 
Right TALEN 
binding sequence 
hGR 
TALEN2 
 
CATTAACTCCTGGTA 
 
gagaagaaaacccca 
 
GCAGTGTGCTTGCTC 
Notch 
TALEN AGGGTCACCCTCATA gactcctgggagttttc ATTGCCCTTGTTTCT 
IL7R GR 
TALEN2 
ATTATGTCTTAACTT tgttcttttacatct TCACAACTAAAGGAA 
IL7R GR 
TALEN3 
ATGTCTTAACTTTGTT cttttacatcttcaca ACTAAAGGAAAGAGAT 
IL7R 
Exon2 
CACTCCTTCTGGTGCC acagccagttggaag TGGATGGAAGTCAACATTT 
IL7R 
Exon3 
ATATATTTTATAAAGAC atcagaattcttact GATTGGTAGCAGCAATAT 
Table 3.7 Binding sites of TALEN pair and spacer sequences on the 5’-3’ coding strand. 
 
 
3.2.3.2 Assembly of custom TALEN constructs using Golden Gate  
TALEN kit 
 
TAL effector DNA binding domain is composed of tandem repeat modules. 12th 
and 13th amino acids within each repeat module, called repeat-variable di-residues 
(RVDs), are responsible for nucleotide recognition. NI, NN, NG and HD are the four 
most common RVDs, each preferentially bind to nucleotides A, G, T, and C, 
respectively. For some of the TALEN constructs in these experiments modules with NH 
RVD was used instead of NN to bind nucleotide G. Design of custom TALE and 
TALENs were performed using TALEN Golden Gate Kit, which was obtained from 
Addgene. The Golden Gate TALEN kit was reported by Cermak et al (2011) and 
contains a set of module plasmids with each individual RVDs, array plasmids for 
intermediate cloning and backbone expression plasmids to make final TALEN 
expression constructs 11 .  
 
The custom TALEN or TAL effector construct is assembled by using successive 
rounds of Golden Gate cloning, in which digestion by Type IIS restriction 
endonucleases such as BsaI and Esp3I is performed to create unique 4 bp overhangs on 
DNA fragments. These unique overhangs flanking each RVD were designed such that 
up to 10 RVD-encoding repeat module plasmids can be ligated in a single reaction. 
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Assembly of repeat modules into array plasmids is followed by assembly of array 
plasmids into final expression vectors (Figure 3.4). Construction of TAL effector or 
TALEN construct was achieved in 5 days (Figure 3.5). 
 
Figure 3.4 Golden Gate assembly of custom TALE and TALEN constructs. 
 
 
Figure 3.5 Timeline for TALEN construction using TALEN Golden Gate kit 11. 
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 Day 1: After identification of possible TALEN target sites and determination of 
the RVD sequence, two separate array plasmids were assembled for “n” RVD repeat 
module containing TALEN expression plasmids. First 10 module plasmids were 
selected according to the order of RVD sequence, and were cloned into array plasmid 
pFUS_A. Then, modules selected for remaining RVDs, the ones from 11 to (n-1) were 
cloned into the array plasmid pFUS_B#n-11. RVD encoding modules for second array 
were selected starting with plasmid #1. Last RVD (#n) was not included in this reaction 
as it was provided by a different, “last repeat” plasmid and included in the second step 
of Golden Gate cloning. 
Golden gate reaction #1 was set according to Table 3.8 for each intermediary 
array plasmid, called as reaction A for first array plasmid and reaction B for the second 
one. For example a TALEN encoding plasmid with 16 repeats was generated by cloning 
10 repeats into the pFUS-A plasmid and 5 repeats into the pFUS-B5 plasmid. The 
contents of these plasmids were transferred in later days of the procedure into the 
pCGoldy-TALEN destination expression plasmid along with the contents of last repeat 
plasmids, in a four plasmid reaction. 
  
Components Used amount 
Each of module vectors 150 ng 
pFUS vector 150 ng 
BsaI (NEB) 1 μL 
BSA (2 mg/ ml) 1μL 
T4 DNA ligase (NEB) 1 μL 
10X DNA ligase buffer 2 μL 
dH2O Up to 20μL 
Total 20μL 
Table 3.8 Components and amounts for Golden Gate reaction #1. 
 
Reactions were incubated in a thermo cycler for following cycle: 
10 X (37°C/5 min + 16°C/10 min) + 50°C/5 min + 80°C/5min 
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In order to degrade unligated linear dsDNA fragments of incomplete ligation 
products, and linearized vectors, 1μL of exonuclease V (RecBCD) (NEB) and 1μL of 
10mM ATP were added to reaction and incubated at 37°C for 30min. After completing 
this procedure, 3.85 μL 100mM EDTA solution was added and the reaction volume was 
completed to 30 μL with water before performing 70°C incubation for 30min to 
inactivate exonuclease V and any remaining active enzymes.  
Chemically competent DH5α E.coli cells were transformed with 2 μL of the 
reaction and plated on LB agar containing 50μg/mL spectinomycin, with X-gal and 
IPTG for blue/white screening of colonies. 
 
Day 2: Correct assembly of TALEN RVD repeat modules into intermediary 
arrays was controlled first by performing colony PCR with 5 white colonies picked 
from each plate. A PCR master mix was prepared according to colony PCR conditions 
shown in Table 3.9 using pCR8_F1 and pCR8_R1 as forward and reverse primers, 
respectively, individual colonies were resuspended in this solution. 
Component Volume 
10X standard Taq buffer(Mg free) 2.5μL 
25 mM MgCl2 2μL 
10mM dNTP each 0.5μL 
Forward primer 0.2μL 
Reverse primer 0.2μL 
Taq polymerase (5U/μl) 0.125μL 
dH2O 19.475μL 
Total 25μL 
Table 3.9 Optimized colony PCR conditions. 
 
PCR was performed according to following cycle; 
95°C/4 min + 30X (95°C/30 s + 55°C/30 s + 72°C/135 s) + 72°C/10 min 
 
Depending on the colony PCR results, two correct clones were inoculated into 3mL LB 
containing 50μg/mL spectinomycin and incubated overnight at 37°C shaking at 200 rpm. 
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Day 3: Plasmid DNA was isolated from overnight cultures of pFUS_A and 
pFUS_B plasmids containing repeats. Correct assembly of array was controlled by 
restriction enzyme digestion with AflII and XbaI and agarose gel electrophoresis. 
Double digestion with these enzymes releases the repeat arrays and size of fragments 
produced was 1048 bp for pFUS_A containing 10 RVDs whereas size of fragments 
varied for pFUS_B plasmids. Correctly assembled intermediary arrays and sequence 
encoding the nth repeat were assembled into the final expression backbone vector. In 
these experiments mammalian expression vector pC-Goldy TALEN was used. For 
Golden Gate reaction# 2, digestion and ligation were performed in 2 steps due to BsmBI 
restriction enzyme working at 55°C which inhibited the activity of T4 DNA ligase. The 
first part of the reaction was set according to Table 3.10. 
 
Components Amount 
Reaction A 150 ng 
Reaction B 150 ng 
pLR vector 150ng 
Expression backbone vector 75ng 
NEB Buffer 4 (10X) 1.5 μL 
BsmBI (NEB) 0.5 μL 
dH2O Up to 15μL 
Total 15μL 
Table 3.10 Components for the first part of Golden Gate reaction #2. 
 
After incubation of the first part of the reaction at 55°C for 10 minutes, the second part 
of the reaction was set according to Table 3.11. 
Components Used amount 
ATP (10 mM) 2 μL 
NEB Buffer 4 (10X) 0.5 μL 
T4 DNA ligase 1 μL 
DTT (0.2M) 1μL 
Water 0.5 μL 
Total 20 μL 
Table 3.11 Components for second part of Golden Gate reaction #2. 
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 Reactions were incubated in a thermo-cycler using the following cycle: 
16°C /15min + 55°C / 15 min + 80°C / 5 min 
 
Chemically competent DH5α E.coli cells were transformed with 2 μL of the reaction 
and plated on LB agar containing 100 μg/mL ampicillin, with X-gal and IPTG for 
blue/white screening of colonies. 
 
Day 4: Colony PCR was performed to check the assembly of intermediary arrays 
into the final expression plasmid and 5 white colonies were picked from the plate. The 
colony PCR mix was prepared according to Table 3, using TAL_F1 and TAL_R2 as 
forward and reverse primers. After resuspending individual colonies in a reaction 
mixture, colony PCR was performed according to the following cycle; 
95°C/4 min + 30X (95°C/30 s + 55°C/30 s + 72°C/3 min) + 72°C/10 min 
Depending on colony PCR results, two correct clones were inoculated into 3mL LB 
containing 100μg/mL ampicillin and incubated overnight at 37°C shaking at 200 rpm. 
 
Day 5: Plasmid DNA was isolated from overnight cultures and correct assembly 
of the final full-length repeat array was verified by restriction enzyme digestion with 
AatII and StuI and agarose gel electrophoresis. In addition, BspEI control digest, which 
cut only in HD modules of 2-10, was performed to determine final array integrity. DNA 
midipreps were prepared from correctly assembled TALEN plasmids, and sequenced 
using the SeqTALEN 5-1 and TAL_R2 primers.  
 
To express TALEN pairs in mammalian cells TALEN constructs should be cloned into 
a destination plasmid that contains promoter for mammalian expression. In these 
experiments six different TALEN pairs were designed using Golden Gate TALEN kit; 
TALEN pairs targeting Notch binding site 78 and GR binding site of IL7R gene 
promoter region, TALEN pairs targeting the 2nd and 3rd exons of IL7R gene and finally 
a TALEN pair targeting the start region of human GR gene. After assembling repeat 
monomers in array plasmids of pFUS_A and pFUS_B, as destination vector pC-Goldy 
TALEN backbone was used.  
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3.2.4 Mammalian Cell Culture 
 
3.2.4.1 Maintenance of mammalian cell lines 
 
In this project a suspension cell line RLM11 was mainly used and it was grown in 
RPMI 1640 cell culture medium that is supplemented with 10% heat inactivated fetal 
bovine serum (FBS), 2 mM L-Glutamine, 100 unit/mL, 100 unit/mL streptomycin, non-
essential amino acids, vitamin and 50 μM 2-mercaptoethanol in tissue culture flasks. 
Additionally adherent cell line HCT116 was used, and it was grown in DMEM cell 
culture medium that is supplemented with 10% heat inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine, 100 unit/mL penicillin and 100 unit/mL streptomycin in 10 
cm tissue culture dishes. All cultures were maintained in a humidified incubator 
supplied with 5% CO2 at 37°C and split into fresh medium when they reach to ~80% 
confluency. TALEN transfected cells were incubated in a humidified incubator supplied 
with 5% CO2 at 32°C after transfection for 72 hours. 
 
For preparation of frozen stocks of both adherent and suspension cell lines, cells at 
exponential growth phase were resuspended in ice-cold freezing medium. They were 
stored at -80°C for 24-48 hours and then transferred to liquid nitrogen tank for longterm 
storage. After thawing, cells were immediately washed with growth medium to remove 
any residual DMSO. 
 
3.2.4.2 Transient transfection of suspension cells 
Transient transfection of suspension cell line, RLM11, was done by using Neon 
electroporation system (Invitrogen). One day before transfection, cells were split 1:10 
ratio. 107 cells were washed twice with filter sterilized 1X PBS. After removal of 
supernatant, 10 μg DNA was added onto pellet and cells were resuspended in 100μL of 
HBS. Mixture was taken into 100μL Neon golden tips and placed in electroporation 
cuvette. Optimum transfection condition for delivery of DNA into cells is 1500 V with a 
single pulse in 20 milliseconds. Then, cells were transferred to tissue culture flasks 
containing pre-warmed RPMI supplemented with 10% FBS, 2 mM L-Glutamine, 100 
unit/mL, 100 unit/mL streptomycin, non-essential amino acids, vitamin and 50 μM 2- 
 mercaptoethanol. TALEN transfected RLM11 cells were incubated at 32°C-incubator 
supplied with 5% CO2 for 72 hours and harvested for further TALEN genotyping assays. 
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3.2.4.3 Transient transfection of adherent cells with PEI 
 
Transient transfection of adherent cell lines was achieved using 
polyethylenimine (PEI). PEI is a cationic polymer, which forms complex with 
negatively charged DNA and bind to cell surface. DNA is taken into the cell via 
endosomal vesicles and osmotic swelling release plasmid DNA to the cytoplasm 79. One 
day before transfection, 2.0 x 105 adherent cells (for each well) were split onto 6 well 
tissue culture plates. On the day of transfection, 3 μg of total DNA was diluted in 200 
μL serum-free DMEM without phenol red in a sterile tube. PEI (1μg/μL) was added to 
diluted DNA based on 3:1 ratio of PEI (μg) to total plasmid DNA (μg) and mixed 
immediately by vortexing. After 15 minutes of incubation at room temperature, 
DNA/PEI mixture was added drop by drop on cells in tissue culture dishes. HCT116 
cells transfected with TALENs were incubated at 32°C-incubator supplied with 5% CO2 
for 72 hours and harvested for further TALEN genotyping assays. 
 
 
3.2.4.4 Flow cytometric analysis 
 
106 cells were used for each flow cytometric analysis. Flow cytometric analysis 
of cells was performed using BD FACSCanto. For analysis of cells expressing 
fluorescent protein GFP, the cells were washed twice with FACS buffer and 
resuspended in 500μL of FACS buffer for analysis. GFP expression levels were 
detected with FITC channel. For analysis of IL7R expression, cells were washed twice 
with FACS buffer and incubated with CD127-Biotin antibody against mouse IL7Rα –
Biotin at 4°C for 30 min in dark. After washing twice with FACS buffer to remove 
unbound antibody, cells were incubated with SA-Alexa647 at 4°C for 30 min in the 
dark. Cells were washed twice with FACS buffer and resuspended 500μL of FACS 
buffer for analysis. IL7R expression levels were detected with Alexa-647 channel. 
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3.2.5 TALEN Induced Mutation Screening 
 
General strategy for detection of mutation at TALEN target site is given in 
Figure 3.6. In this study, mutation in TALEN target site was detected by the loss of 
restriction enzyme cut site, via restriction fragment length polymorphism (RFLP) assay. 
 
 
 
Figure 3.6 General strategy for detection of TALEN induced mutation at target the site. 
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3.2.5.1 Genomic DNA extraction 
72 hours after transfection with TALENs, genomic DNA of the cells was 
isolated by using GenElute Mammalian Genomic DNA Miniprep Kit (SIGMA). 
 
3.2.5.2 Restriction Fragment Length Polymorphism (RFLP) analysis 
Isolated genomic DNA was amplified via PCR reaction before performing 
digestion. (Optimized PCR conditions given in Table 3.12 using primers for TALEN 
target site amplification.) 
 
 Component   Amount 
Template genomic DNA 1.0μL 
Taq Polymerase Buffer 10X  2.5μL 
10mM dNTP each 0.4μL 
Forward primer (10mM) 1.0μL 
Reverse primer (10mM) 1.0μL 
Taq Polymerase (5U/μl) 0.2μL 
dH2O 18.9μL 
Total 25μL 
Table 3.12 Optimized PCR conditions for TALEN target site amplification 
 
PCR was performed according to following cycle for the respective region: 
GR binding site (also NFkB site): 
95°C/4 min + 30X (95°C/30 s + 54°C/30 s + 72°C/60 s) + 72°C/10 min 
Notch binding site; 
95°C/4 min + 30X (95°C/30 s + 64°C/30 s + 72°C/60 s) + 72°C/10 min 
Exon 2 and Exon 3; 
95°C/4 min + 30X (95°C/30 s + 60°C/30 s + 72°C/60 s) + 72°C/10 min 
hGR TALEN binding site: 
95°C/4 min + 30X (95°C/30 s + 62°C/30 s + 72°C/60 s) + 72°C/10 min 
 
PCR products were digested with the enzyme in spacer region and run on 
agarose gel to detect whether any undigested band is left indicating presence of 
mutation at TALEN target site. 
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3.2.5.3 Single Cell Analysis 
 
TALEN expression in mammalian cells induces random and different mutations 
and most of the cells remain intact after transfection. For that reason single cell analysis 
was done to amplify one type of mutation and observe its effects on a batch of cells that 
has the same specific change in their sequence. While growing single cell colonies there 
are two strategies that can be followed. In the first one after the cells were counted serial 
dilutions were done in their respective growth medium and when the total number of 
cells that were desired reached (less than 90 cells for one plate), the medium was 
divided to 96-well plates. After 7-10 days single cells had enough confluency to transfer 
to a larger volume. In the second one, certain amount of cells were put into the first lane 
of the 96-well plate and serial dilutions were done in the 96-well plate itself. Only the 
cells that were grown right before the empty wells were chosen to do further 
experiments. Figure 3.7 explains the dilution methods.  
 
 
Figure 3.7: Methods for obtaining single cell colonies. 
 
After growing single cell colonies mutants are detected either by RFLP analysis 
after genomic DNA isolation or by FACS analysis by comparing their IL7R expression 
levels to the WT (only for the experiments done with RLM11 cell line).  
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In order to sequence suspected mutants gel extraction was performed for the 
band in size of the undigested PCR product (in case there is still a band that can be 
digested) and cloned using CloneJETTM PCR Cloning Kit (Thermo Scientific) or InsTA 
Clone PCR Cloning Kit (Thermo Scientific). Uncut bands were cloned to pJET1.2/blunt 
or pTZ57R/T vector and colony PCR was performed to ensure presence of insert in 
selected colonies according to conditions provided by the kit. Plasmid DNA was 
isolated from 3-ml overnight cultures of true colonies and sequenced to evaluate 
mutations generated at the cleavage site. 
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RESULTS 
 
  
 4.1.Targeting IL-7R Gene 
 
4.1.1. Targeting Transcription Factor Binding Sites of the IL-7R Gene 
 
 In this study we used TALEN genome editing tools to mutate two of the 
transcription factor binding sites in the IL-7R enhancer region, the glucocorticoid 
receptor (GR) binding site and the Notch binding site (Figure 4.1). First, we constructed 
two pairs of different TALEN proteins targeting the GR binding site of the IL-7R gene 
using the Golden Gate TALEN Assembly procedure as explained in the Methods 
section. The TALEN pair targeting the Notch binding site was designed by Şeyda 
Temiz 78. Using the same method we expressed both Notch TALENs and GR TALENs 
in the IL-7R positive murine cell line RLM11 to observe the effects of mutations 
occurring in these regions on the expression of the IL7R gene. We hypothesized that if 
the binding of one of these transcription factors to their corresponding sites had a 
positive critical role in the expression of the IL-7R protein, the introduced mutations 
would decrease the IL-7R expression levels in these cells.  
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Figure 4.1 Schematic representation of the mouse IL7Rα gene locus. The IL7Rα gene 
contains eight exons and three evolutionarily conserved regions (ECR). ECR3 has 
binding sites for Gata, NFkB, GR and Foxo. Notch binds upstream of the ECR2. Two 
transcription factor binding sites targeted in this study were the GR and Notch binding 
sites. 
 
 
4.1.1.1. TALENs Targeting GR Binding Site of IL-7R 
 
 We designed and constructed two pairs of TALENs for this experiment; one of 
the pairs, named as GR TALEN2 directly targeting the GR binding site, and the other 
pair, GR TALEN3 targeting a slightly shifted region, placing an MboII restriction 
enzyme recognition site in the middle. Since we use the restriction fragment length 
polymorphism (RFLP) assay to detect mutations as summarized in Figure 3.6, we 
assumed selecting mutated colonies would be easier in case the TALEN3 pair was used, 
while the TALEN2 pair would be more successful in mutating the GR binding site. 
Their binding sites and the targeted region are shown in Figure 4.2. 
 
While designing the TALEN pairs, we paid attention to having 15 to 16 bp long 
spacers in between the pairs since it has been shown that longer or shorter spacer length 
results in reduced functional activity. In addition, having a 5’T base preceding the 
TALEN pair binding sites is important for their binding efficiency; therefore, all of the 
TALENs we designed have a T nucleotide right before the first base they bind. Since 
the right TALENs, or reverse TALENs, bind the complementary strand, in Figure 4.2 
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the preceding base appears to be adenine. Both monomers of the TALEN2 pair binds a 
region that is 15 nucleotides long while the TALEN3 pair binds a region that is 16 
nucleotides long.  
 
 
Figure 4.2 Binding sites for the TALENs targeting the GR binding site. The yellow 
arrow indicates the GR transcription factor binding site, pink and purple ones indicate 
the left and right TALEN pairs that were numbered as 2 and 3. Light pink arrow shows 
an MboII restriction enzyme recognition site, and it cuts a site 7 nucleotides away. 
Green arrows indicate the neighboring transcription factor binding sites and the black 
arrows show the primers used to amplify this region. 
 
 
4.1.1.1.1. Assembly of GR Site Targeting TALENs 
  
 In order to construct the TALENs targeting the GR binding site, we used the 
Golden Gate TALEN Assembly kit as described in the Methods section (Figure 3.4). 
TALEN assembly takes 5 days and involves two main reactions for the assembly of 
individual repeat modules into array plasmids and assembly of array plasmids into a 
final mammalian expression plasmid. We used NI, HD and NG RVD modules to 
recognize and bind A, C and T nucleotides respectively and as G nucleotide recognizing 
RVD we used NH, differing from the previously designed TALENs in our lab (as was  
52 
 
the case for the Notch site RVDs). This modification was because of recent experiments 
that showed that NH RVDs are more specific in binding G than NN 15. 
  
 
Figure 4.3 Plasmid maps showing GR TALEN2 Left and Right TALEN pair repeats in 
pFUS_A and pFUS_B4 intermediary plasmids after Golden Gate Reaction #1. 
 
For the construction of four different TALENs with 15 and 16 repeats we cloned 
first 10 repeats in pFUS_A plasmids and the remaining ones except the last ones were 
cloned into pFUS_B4 and pFUS_B5 (Golden Gate Reaction #1).  Therefore, we set up 
two Golden Gate reactions (reaction A and B) for each monomer of the TALEN pair. 
We transformed the Golden Gate reaction #1 into E. coli, plated the reactions on agar 
plates with spectinomycin and used IPTG/X-gal for blue-white screening. We 
performed colony PCR on white colonies using the primers pCR8_F1 and pCR8_R1. 
For repeats in the pFUS_A plasmids, we detected bands around 1200 bp, whereas for 
the pFUS_B4 and pFUS_B5 plasmids, we obtained bands around 600 bp and 700 bp 
respectively. In addition to the band of expected size, a smear and ladder of bands were 
also detected which results from the presence of repeats in clones. After isolation of 
plasmid DNA from two different correct colonies, we performed an AflII-XbaI 
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diagnostic digest which should generate bands reflecting the number of repeats such 
that a 1048bp-band was obtained for a pFUS_A plasmid with 10 repeats. Similarly the 
band sizes were 430bp and 523 bp for the pFUS_B4 and pFUS_B5 plasmids with four 
and five repeats. Figure 4.3 and Figure 4.4 show plasmid maps related to reactions A 
and B of the GR TALEN2 and GR TALEN3 left and right pairs. Figure 4.5 shows 
agarose gel images after colony PCR with pCR8_F1 and pCR8_R1 primers and 
confirmation of those colonies with AflII-XbaI double digests. 
 
 
 
 
Figure 4.4 Plasmid maps showing GR TALEN3 Left and Right TALEN pair repeats in 
pFUS_A and pFUS_B4 intermediary plasmids after Golden Gate Reaction #1. 
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Figure 4.5 Agarose gel images showing colony PCR results and control digests done to 
find correctly assembled array plasmids for both TALEN2 and TALEN3 pairs after 
Golden Gate Reaction #1. 
 
 
After the construction of intermediary array of repeats were complete, we joined 
repeats coming from reactions A and B, the last repeat plasmids and the final backbone 
plasmid pC-GoldyTALEN in Golden Gate reaction #2. This time after transformation 
the colonies were grown on ampicillin agar plates and we performed colony PCR using 
primers TAL_F1 and TAL_R2, which gives bands around 1740bp for plasmids with 15 
repeats and 1840bp bands for plasmids with 16 repeats. Along with the correct bands a 
ladder effect and a smear is expected. Consistent with this, we found that the colonies 
that give a single band were not correctly assembled. After isolating plasmid DNAs of 
correct colonies we performed a confirmation digest with the AatII and StuI enzymes, 
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which generate bands sized 1724bp for plasmids with 15 repeats and 1826bp for 16 
repeats. Figure 4.6 and Figure 4.7 shows plasmid maps of the GR binding site TALEN 
pairs GR TALEN2 and GR TALEN3 in their final plasmid pC-GoldyTALEN. Figure 
4.8 shows agarose gel images after colony PCR with TAL_F1 and TAL_R2 primers and 
control digests with AatII-StuI. 
 
 
 
Figure 4.6 Plasmid maps showing fully assembled GR TALEN2 Left and Right TALEN 
pair in pC-GoldyTALEN backbone. 
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Figure 4.7 Plasmid maps showing fully assembled GR TALEN3 Left and Right TALEN 
pair in pC-GoldyTALEN backbone. 
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Figure 4.8 Agarose gel images showing colony PCR and control digest results of GR 
TALEN2 and GR TALEN3 pairs after Golden Gate reaction #2. 
 
 
4.1.1.1.2. Expression of the Constructed GR TALEN Pair in RLM11 cells and 
Detection of Site Specific Mutations 
 
After we completed the construction of two different TALEN pairs targeting the 
GR binding site of the IL-7R gene, we wanted to confirm their functionality. We used 
the RLM11 cell line, a mouse thymoma cell line which has a high level of IL-7R 
expression on its surface. We assumed that any damage induced on the gene control 
elements would easily be observed on the expression phenotype of the cell surface 
protein.  We first transfected RLM11 cells with the GR TALEN3 pair using the Neon 
electroporation system. Because this TALEN target site had an MboII restriction 
enzyme binding site in its spacer region, we expected to find mutations induced easier 
than the second TALEN pair whose activity cannot be assessed using RFLP. After the 
cells were transfected, we incubated the cells in 32oC for 72 hours and at the end of this 
period we analyzed the cells by flow cytometry (Figure 4.9). We have observed that 
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even though IL-7R levels dropped for GR TALEN transfected cells, the cells we 
transfected with pcDNA-GFP plasmid for transfection efficiency control had lower 
IL7R levels as well. We observed this result probably because the cells could not regain 
their health after electroporation and 32oC incubation. Therefore we could not relate this 
result to TALEN function. 
 
Figure 4.9 IL-7R expression levels of pcDNA-GFP and GR TALEN3 transfected 
RLM11 cells compared to untransfected cells. Histogram for Alexa-647 represents 
surface IL-7Rα expression. 
 
Since IL-7R levels only could not indicate the existence of a mutation, we 
extracted the genomes of both untranfected and TALEN transfected samples and 
performed the RFLP assay (as explained in Figure 3.6). We PCR amplified the region 
with the indicated primers in Figure 4.2 and digested the amplicons with the MboII 
restriction enzyme. We have observed an uncut band in TALEN transfected samples, 
indicating that a large portion of the cells were mutated (Figure 4.10). 
 
 
Figure 4.10 RFLP analysis on the GR TALEN transfected and untransfected 
RLM11 cells. The uncut band the red arrow indicates the presence of mutation. 
 
59 
 
4.1.1.1.3. Single Cell Screening of GR TALEN transfected RLM11 cells and 
Detection of Mutants 
 
 Since we could not detect any significant changes in the phenotype of the 
TALEN transfected pool of cells, and assuming that the presence of unmutated cells in 
the pool could be preventing the detection of mutated cells, we decided to grow single 
cell colonies from this pool and screen for cells that have mutations, preferably on both 
chromosomes. The strategy to obtain single cell colonies is explained in Figure 3.7. 
After a portion of the single cells we plated grow, we analyzed their mutation status by 
RFLP and separated the ones that had uncut bands (Figure 4.11). 
 
 
Figure 4.11 RFLP results for GR TALEN transfected single cell colonies. Red arrows 
show the uncut bands caused by the presence of a mutation in the restriction enzyme 
recognition site. UT stands for untransfected. 
 
After repeating the experiment to ensure that all of the colonies we selected are mutants, 
(Figure 4.12) we gel extracted the uncut bands and cloned them into the pTZ57R/T 
plasmid using the InsTAclone PCR cloning kit to send them to MCLAB Inc. (San 
Francisco, CA, USA) for sequencing.  
 
 
Figure 4.12 Selected RLM11 single cell colonies to send sequencing. 
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Sequencing results of the selected mutant colonies demonstrated the presence of several 
types of mutations (Figure 4.13). All of the mutations had disrupted the GR binding site, 
however, the 2nd, 9th and 15th colonies still had an intact wild type sequence along with a 
mutated allele.  
 
 
 
Figure 4.13 Sequencing results of single cell colonies that had uncut bands in the RFLP 
assay. Yellow highlighted sequences indicate TALEN binding sites, green letters 
indicate the GR binding region, underlined sequence is the MboII restriction enzyme 
binding site and red letters show the insertion sequence. 
 
4.1.1.1.4. IL-7R Expression in GR binding site Mutant RLM11 cells 
 
After selecting the mutant single cell colonies that had their GR binding site 
disrupted at least in one of their chromosomes, we wanted to compare their IL-7R 
expression levels to wild type RLM11 cells. While one of the single cell colonies, the 
10th colony, had shown lower levels of IL7R expression compared to wild type 
consistently, the rest of the colonies had IL7R expression around the same levels as the 
wild type, and some of them had even significantly higher expression levels in repeated 
experiments. An example FACS analysis from each colony is shown in Figure 4.14.   
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Figure 4.14 FACS analysis showing IL7R expressions of mutant RLM11 single cell 
colonies. Histogram for Alexa-647 represents surface IL-7Rα expression. 
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4.1.1.2 TALENs Targeting Notch Binding Site of IL-7R gene 
 
In a previous study done in our lab IL7R Notch binding site targeting TALENs 
were assembled and different mutations caused by imprecise repair of double strand 
breaks induced by these TALENs were analyzed in Neuro-2a and RLM11 cell lines 78. 
The experiments were performed in a pool of cells that contained a majority of wild 
type cells along with the cells with various mutations induced by TALEN transfection, 
which made them unsuitable for IL7R expression experiments. In this study, we wanted 
to continue this project by growing single cell colonies from these TALEN transfected 
pools and observe the effect of specific Notch site mutations on IL7R expression levels. 
The Notch TALEN pair binding sites and the targeted region is shown in Figure 4.15. 
 
 
 
Figure 4.15 The binding sites for IL-7R Notch site targeting TALEN pair. Yellow arrow 
indicates the RBPJk-Notch binding site, the flag in between shows the sequence 
restriction enzyme BstNI cuts, the black arrows indicate the primers that were used to 
amplify this region. 
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4.1.1.2.1 Expression of a previously designed Notch TALEN pair in RLM11 cells 
and mutation screening via expression of IL-7R in single cell colonies 
 
We transfected the RLM11 cell line with the expression constructs encoding 
Notch TALEN pair and compared the IL-7R expression levels of untransfected and 
transfected cells by FACS analysis and observed that even though Notch TALEN 
transfected cells had lower expression, it was not significant (Figure 4.16). 
 
Figure 4.16 IL-7R expression levels of Notch TALEN transfected RLM11 cells 
compared to untransfected cells. Histogram for Alexa-647 represents surface IL-7Rα 
expression. Red histogram shows WT expression while blue histogram shows the IL7R 
expression on transfected cells. 
 
 
Figure 4.17 RFLP analysis on the Notch TALEN transfected and untransfected RLM11 
cells. The uncut band which is pointed by a red arrow indicates the presence of a 
targeted mutation. 
 
Along with FACS analysis we checked the presence of a mutation by using the 
RFLP assay (Figure 4.17) and even though we observed an uncut band the percentage 
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was too low compared to our GR TALEN transfected cells. For that reason while 
screening for mutant colonies among single cells instead of extracting genomic DNA 
from hundreds of colonies and performing the RFLP assay we followed a different 
approach. We expected that the Notch binding site mutated cells would have lower 
expression of the IL-7R protein if Notch had a positive role in the expression of IL7R. 
Therefore, we screened only colonies that had lower IL7R expression levels. We 
predicted that this approach would increase our chance of finding mutated colonies. 
Single cell colonies were grown as explained in Figure 3.7 using the first method and 
after about two weeks we performed FACS analysis on 91 single cell colonies. We 
selected colonies that had significantly lower IL-7R expression to continue with further 
experiments (Figure 4.18). 
 
 
Figure 4.18 IL-7R expression levels of Notch TALEN transfected RLM11 single cell 
colonies that have lower expression levels compared to WT expression. Histogram for 
Alexa-647 represents surface IL-7Rα expression. Red histograms show the expression 
on untransfected cells while blue histograms show the expression levels on colonies 
being examined. 
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4.1.1.1.2. Detection of mutation in suspected Notch TALEN transfected single cell 
colonies 
 
After eliminating a large portion of the candidate mutant single cell colonies due 
to their existing IL-7R expression we predicted that it would be easier to find mutated 
single colonies by performing the RFLP assay. We extracted genomic DNA from these 
colonies and digested with the BstNI enzyme which had a cut site in the middle of 
Notch binding sequence. According to RFLP, from around 20 colonies only two 
appeared to be mutated; 35th and 49th (Figure 4.19). 
 
 
Figure 4.19 RFLP assay for Notch TALEN transfected RLM11 single cell colonies. The 
restriction digestion was done with the BstNI enzyme and the red arrows show the 
uncut bands which indicate the presence of mutations. 
 
 
Figure 4.20 IL-7R expression levels for Notch binding site mutated RLM11 cells.  
Histograms for Alexa-647 represents surface IL-7Rα expression. 
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The single cell colonies that were confirmed to be mutated through RFLP 
analysis had significantly lower IL-7R expression compared to IL-7R expression on WT 
RLM11 cells (Figure 4.20). However, the single colonies #30 and #74 showed the 
lowest expression levels. We examined the type of mutations that disrupted the Notch 
binding site of the colonies with uncut bands in the RFLP assay. It is possible that some 
colonies contained mutations that we could not detect by RFLP. Therefore, we cloned 
PCR products that contained the mutation region into the pJET1.2/blunt plasmid using 
the CloneJET PCR kit and sent 8 different colonies for sequencing. Sequencing analysis 
showed that the 35th colony had two types of mutation, a deletion and an insertion; 
along with an intact WT binding site. The 30th and the 74th colonies appeared to be all 
WT and 49th colony despite having an uncut band, had only PCR products with the 
undisrupted binding site cloned (Figure 4.21). 
 
 
Figure 4.21 The sequencing results for Notch site mutated single cell colonies #35, #49, 
#30 and #74. The green letters indicate the Notch binding site, yellow highlighted letters 
show the regions TALEN pair binds, underlined letters are the recognition site for 
BstNI restriction enzyme.  
 
Among the single cell colonies that had lower IL-7R levels compared to WT 
expression the 74th colony was the lowest one, and in contrast to others it was the only 
one that had a complete down-regulation profile. For that reason, we hypothesized that 
this could be due to a much larger deletion in the genome than we could amplify with 
our Notch primers. We performed PCR with primers that were used to amplify ECRs 
(shown in Figure 4.22) along with the Notch primers to see if any of the sites included 
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one of the Notch primers were deleted, however the 74th colony still gave the same band 
as the WT (Figure 4.23). If the deletion still exists and both of the Notch primers are 
deleted, these experiments would not give the results we expected to see.  
 
 
Figure 4.22 The IL7R gene ECR2-ECR3 locus. Blue arrows show ECR2 and ECR3 of 
the IL7R gene, the Notch binding site is in between these regions indicated by a yellow 
arrow, red arrows at the left and right sides are TALEN binding sites. Primers that are 
used to amplify the Notch site are shown with black and primers that are used to 
amplify ECR2 and ECR3 are shown with green arrows. 
 
 
Figure 4.23 PCR amplification of the 74th colony with different primers. Kpl11 forward 
and Notch reverse primers give bands around 2360bp and Notch forward and Kpl12 
reverse primers gives band around 2020bp in WT genome. The binding sites of the 
primers are shown in Figure 4.22. 
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 4.1.2. Use of TALENs to Delete an Entire Intronic Region of IL-7R gene 
 
 One of the evolutionarily conserved regions of the IL-7R gene, ECR1, is in 
between the second and the third exons. Along with the transcription activator binding 
sites in the upstream enhancer region of this gene we wanted to target this ECR site also, 
but differing from the previous experiments instead of targeting one specific binding 
site, we planned to delete the whole intron in between the 2nd and the 3rd exons using 
two TALEN pairs simultaneously. We designed the TALEN pairs to target the exons 
directly, assuming that if both pairs cut the DNA at the same time, the site in between 
them would be removed. To ensure that the exons remained intact while the intron site 
is removed, we used a donor DNA which had exon 2 and 3 fused to each other so that 
when the double strand breaks were induced by the TALEN pairs at the same time, the 
region would be repaired according to the donor DNA by homologous recombination. 
The strategy to remove intron 2 of the IL7R gene by TALENs is explained in Figure 
4.24.  
 
 
Figure 4.24 The strategy to delete the ECR1 region of the IL-7R gene using two 
TALEN pairs and a homologous donor DNA. 
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4.1.2.1. Assembly of TALENs targeting Exon 2 and Exon 3 of the IL-7R gene  
  
In order to remove the region in between exon 2 and 3 we designed two separate 
TALEN pairs to target random sites in the middle of the exons. As we did with the 
previous designs we had 5’T nucleotides preceding the TALEN binding site, 15 
nucleotide long spacer regions, and a restriction enzyme cut site in the middle to 
perform RFLP assays for detecting potential mutations. Exon 2 (E2) TALEN left and 
right pair have 16 and 19 repeats while Exon 3 (E3) TALEN left and right pair have 17 
and 18 repeats respectively. Figure 4.25 and Figure 4.26 shows the Exon 2 and Exon 3 
regions, the TALEN pair binding sites and the primers that were used to amplify those 
regions.  
 
 
 
Figure 4.25 Binding sites of TALENs targeting Exon 2 of IL-7R gene. Magenta arrows 
indicate TALEN binding sites, black arrows show the primers that were used to amplify 
this region, the flag in the spacer region of TALEN pair shows the restriction enzyme 
BsrI cut site. 
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Figure 4.26 Binding sites of TALENs targeting Exon 3 of IL-7R gene. Purple arrows 
indicate TALEN binding sites, black arrows show the primers that were used to amplify 
this region, the flag in the spacer region of TALEN pair shows the restriction enzyme 
EcoRI cut site. 
 
Figure 4.27 Plasmids maps of the Exon 2 targeting TALEN pair in pFUS_A and 
pFUS_B intermediary plasmids after Golden Gate reaction #1 
71 
 
 We assembled the TALEN pairs using the Golden Gate Assembly kit. First 10 
repeat modules were cloned into the pFUS_A plasmid and the remaining repeats except 
the last repeat were cloned into the pFUS_B plasmid of the respective number in 
Golden Gate reaction #1. After the transformation of the ligated array of repeats in the 
intermediary plasmids along with IPTG/X-gal blue-white screening, we chose the white 
colonies to perform colony PCR using the pCR8_F1 and PCR8_R1 primers. We 
expected to see bands sized 1200bp for pFUS_A that has 10 repeats and bands sized 
700bp, 800bp, 900bp and 1000bp for pFUS_B5, pFUS_B6, pFUS_B7 and pFUS_B8 
respectively. Along with the correct sized band a smear and a ladder effect caused by 
the repeats is also observed, consistent with the Golden Gate protocol. After choosing 
the correct colonies we isolated their DNA to do a confirmation digest with AflII and 
XbaI. The 10 repeats in pFUS_A gives a 1048bp band while B5, B6, B7 and B8 give 
bands sized 523bp, 622bp, 720bp, and 820bp respectively. The plasmids maps for Exon 
2 and Exon 3 TALEN pairs are shown in Figure 4.27 and Figure 4.28 and agarose gel 
images of colony PCR and control digest results for both pairs are shown in Figure 4.29.   
 
 
Figure 4.28 Plasmids maps of Exon 3 targeting TALEN pair in pFUS_A and pFUS_B 
intermediary plasmids after Golden Gate reaction #1 
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Figure 4.29 Agarose gel images showing colony PCR and control digest results of Exon 
2 and Exon 3 targeting TALENs after Golden Gate reaction #1 
 
 
Figure 4.30 Plasmid maps for fully assembled Exon 2 targeting TALEN pair in their 
final expression vector pC-GoldyTALEN. 
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Figure 4.31 Plasmid maps for fully assembled Exon 3 targeting TALEN pair in their 
final expression vector pC-GoldyTALEN. 
 
After the intermediary plasmids for TALEN repeats were assembled, we joined 
the pFUSA and pFUS_B plasmids together with the plasmid of the last repeat to the 
final expression plasmid named pC-GoldyTALEN in Golden Gate reaction #2. After 
transformation we searched for correct colonies performing colony PCR with the 
TAL_F1 and TAL_R2 primers, expecting to see bands around 1800bp-2000bp along 
with a smear and a ladder effect. After choosing 2 of the colonies that seemed to be 
correct, we isolated their DNA to perform a double digest with StuI and AatII. E2 Left 
TALEN should give a band sized 1826bp; E2 right 2132bp, E3 left 1928bp and lastly 
E3 right should be 2030bp.  Figure 4.30 and Figure 4.31 show the plasmid maps for 
TALEN pairs in their final expression plasmid and Figure 4.32 shows the agarose 
images for colony PCR and control digest results for the final constructs after Golden 
Gate reaction #2.  
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Figure 4.32 Agarose gel images of colony PCR and control digest results of both Exon 
2 and Exon 3 targeting TALENs after Golden Gate reaction #2. 
 
 
4.1.2.2. Expression of Exon2 and Exon3 TALEN pairs in RLM11 cells and 
detection of mutations 
 
After the TALENs were assembled, we first transfected RLM11 cells with the 
Exon 2 and Exon 3 TALEN pairs separately to see if they function on their own, before 
starting with the contransfection experiments. After the transfection and TALEN 
expression were complete, we performed FACS analysis, expecting to see a decrease in 
IL-7R expression even in the pools, considering the fact that we directly targeted exons 
this time. Although we expected IL-7R levels of TALEN transfected cells to be 
significantly lower, it was possible that this effect would be partially due to 
electroporation and 32oC incubation. (Figure 4.33) To confirm these results we 
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performed the RFLP assay on the transfected cell pools and observed a clear uncut band 
for both; indicating that a quite large portion of the cells in the population were mutated 
(Figure 4.34). 
 
 
Figure 4.33 FACS analysis of Exon 2 and Exon 3 TALEN transfected RLM11 
cells. Histogram for Alexa-647 represents surface IL-7Rα expression. Red histogram 
represents WT while the blue ones represent transfected cells. 
 
 
 
 
Figure 4.34 RFLP assay of the Exon 2 and Exon 3 TALEN transfected RLM11 cells. 
Exon 2 and Exon 3 were amplified using the primers shown in Figure 4.25 and Figure 
4.26. Exon 2 PCR products were digested with BsrI enzyme while Exon 3 PCR 
products were digested with EcoRI. Pool#1 and Pool#2 stands for the pool of cells taken 
from the transfected samples at two different times; #1 right after 72h incubation 
including the dead cells after electroporation and #2 only the live cells that were grown 
after a few splits. Red arrows show the uncut bands caused by the presence of mutation. 
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4.1.2.3. A map of the donor plasmid targeting the ECR1 region between Exon 2 
and 3 by homologous recombination 
 
The donor plasmid to repair the IL-7R gene with homologous recombination 
after double strand breaks were induced by the E2 and E3 TALENs was previously 
generated by Gamze Günal in the Erman laboratory 77. If homologous recombination is 
successful, this donor DNA will replace the Exon2-Intron2-Exon3 region of the IL7R 
gene and result in a new allele that has no Intron 2 and a fused Exon2 and Exon3. The 
protein encoded by this allele will be identical to the wild type IL7R protein. Exon 2 
and Exon 3 PCR products were fused to each other using the strategy that was explained 
in Figure 3.1 of the Methods section and this amplicon was cloned into the 
pJET1.2/blunt plasmid using a CloneJET PCR cloning kit. After growing colonies from 
a glycerol stock and performing control digest with the XhoI-XbaI enzymes to make 
sure that the 600bp insert is still in this plasmid, we extracted the digested bands. Figure 
4.35 shows the plasmid map of the construct and the control digests that were done to 
confirm the presence of Exon 2 and Exon 3 fusion PCR product. 
 
 
Figure 4.35 The plasmid map for the E2-E3 fusion product and the agarose gel image of 
the control digest. 
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4.1.2.4. Simultaneous transfection of the Exon2, Exon3 TALENs and the donor 
dsDNA in RLM11 cells 
 
After confirming the activity of TALENs, we co-transfected RLM11 cells with 
both TALEN pairs and the homologous dsDNA donor.  We used a 1:1 molar ratio for 
the total amount of TALENs and the donor dsDNA. Along with the main experiment 
we set up control experiments that we put the same amount of TALEN pairs with the 
co-transfection and complete the rest with mock DNA. After a 72h incubation at 32oC 
we isolated genomic DNA and performed the RFLP assay (Figure 4.36).  In the RFLP 
assay, with cells transfected with only one of the pairs we detected uncut bands, 
indicating that these TALENs could mutate a significant proportion of the cells. Cells 
co-transfected with both TALEN constructs (4 plasmid in total) appeared to have 
slightly fainter uncut bands, which might indicate that both TALENs worked at the 
same time and removed the region in between. We also performed a PCR using forward 
primer of exon 2 and the reverse primer of exon 3 on the co-transfected sample and saw 
a band which corresponds to fused exon 2 and exon 3, however the sample only went 
through a dense medium split after the transfection and probably still contained the free 
donor DNA; we did not see this band in the pool after two more splits.  
 
 
Figure 4.36 RFLP assay for Exon 2 and Exon 3 TALEN pair co-transfection. Exon 2 
and Exon 3 were amplified using the primers shown in Figure 4.25 and Figure 4.26. 
Exon 2 PCR products were digested with BsrI enzyme while Exon 3 PCR products 
were digested with EcoRI. The last lane was PCR amplified by the Exon 2 forward and 
Exon 3 reverse primers. Red arrows show the uncut bands caused by the presence of 
mutation. 
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After a few splits and making sure that the cells recovered their health after 
transfection, we performed FACS analysis on the samples to compare their IL-7R 
expression levels to WT expression. All of the transfected cells, the ones with Exon2 
TALEN pair only, Exon3 TALEN pair only and the co-transfected ones had lower IL-
7R expression compared to untransfected samples (Figure 4.37). All of these results 
were obtained from a pool of cells that still had wild type cells in majority. Experiments 
are continuing with the single cell colony screening.  
 
 
Figure 4.37 FACS analysis of Exon 2 and Exon 3 TALEN transfection and co-
transfection in RLM11 cells. Histogram for Alexa-647 represents surface IL-7Rα 
expression. Red histogram represents WT while the blue ones represent transfected cells. 
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4.2. Targeting GR gene 
 
4.2.1. TALENs Targeting human GR gene to induce Knock-In and 
      Knock-Outs 
 
As we worked on the project that targets the transcription factor GR binding site 
of the IL-7R gene, we also approached the project from another side; we designed a 
TALEN pair against the glucocorticoid receptor gene itself to knock out the gene to see 
which genes would be affected from its absence; and by using the same TALEN pair 
and a homologous donor plasmid we designed, we aimed to insert Venus-YFP gene at 
the same site to make it fused to GR gene so that when they were expressed we could 
track GR protein’s location within the cell when exposed to certain conditions. 
 
 To knock out the hGR gene, we designed TALENs that target a region near to 
translation start codon so that in case the cell fails to repair the gene after the TALEN 
pair induces a double strand break, non-homologous end joining would generate 
insertions or deletions that would cause frameshifts in the coding strand that would end 
up with a non-functional transcript. In case we provide a donor plasmid that is partly 
homologous to the region we induce mutation, through homologous recombination the 
changes we had done in the donor gene would transfer to the genome. For this 
experiment we designed a plasmid that has homologous sites to the genome on the left 
and right sides, and we aimed to insert puromycin resistance and Venus-YFP genes in 
the middle with no stop codons in between. Puromycin resistance would enable us to do 
selection among the ones that has the insert, and P2A sequence in between venus and 
puromycin genes would permit the translation of the transcript without detachment of 
the ribosome in between but have puromycin cleaved off from the venus-hGR complex 
right after the translation occurs so that the puromycin resistance in the cell would not 
interfere with their activity. The strategy to construct this donor plasmid is explained in 
Figure 3.2 of the Methods section and the strategy to knock-out or induce knock-ins in 
hGR is shown in Figure 4.38. 
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Figure 4.38 The strategy to knock out human glucocorticoid receptor using TALENs 
and insert Venus and puromycin resistance genes using homologous recombination. 
 
4.2.2. Assembly of TALENs targeting translation start site of the hGR gene 
  
 We designed TALENs targeting hGR gene using the same methods and paying 
attention to similar things with the ones that was explained in section 4.1.1. The 
TALEN pair has 15 nucleotide spacer length in between, they are preceded by a 5’T 
nucleotide and there is a restriction enzyme recognition site in between to enable usage 
of RFLP assay to select mutants. The binding sites of the TALEN pair, the spacer 
region, and the start codon is shown on Figure 4.39. 
 
Both left and right TALENs have 15 repeats, therefore in the Golden Gate 
reaction #1 we cloned first 10 repeats into pFUS_A array plasmid and four remaining 
ones in pFUS_B4. We had done IPTG/X-gal blue-white screening and had done colony 
PCR to the white colonies using pCR8_F1 and pCR8_R1 primers. The correct colonies 
gave 1200bp bands for 10 repeats and 600bp for 4 repeats. The plasmid maps and 
agarose gel images of the colony PCR products can be seen in Figure 4.40 and Figure 
4.41. 
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Figure 4.39 The binding sites of the hGR TALEN pair on the hGR gene start region. 
Purple arrows indicate TALEN binding sites, black arrows indicate the primers that was 
used to amplify this region, red arrow shows MboII recognition site, note that it cuts a 
different region than the recognition site. The letters show the translated codons, first 
green methionine indicates the start codon. 
 
 
Figure 4.40 The plasmid maps for hGR right and left TALENs in pFUS_A and pFUS_B 
intermediary plasmids after Golden Gate reaction #1 
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Figure 4.41 Agarose gel images of the colony PCR results of hGR TALENs after 
Golden Gate reaction #1 
 
 
We joined the repeats in pFUS_A and pFUS_B plasmids along with the last 
repeats in pC-GoldyTALEN backbone with Golden Gate reaction #2. Using TAL_F1 
and TAL_R2 primers we performed colony PCR expecting to see 1744bp bands along 
with a smear and ladder effect. Control digests were done with StuI and AatII, resulting 
in 1724bp band in between the ~1000bp and ~5000bp bands coming from pC-
GoldyTALEN expression vector. The plasmid maps of fully assembled hGR TALEN 
pair is shown in Figure 4.42 and agarose gel images after colony PCR and their 
confirmation with AatII-StuI double digest is shown in Figure 4.43. 
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Figure 4.42: Plasmid maps of hGR left and right TALEN pair in pC-GoldyTALEN 
backbone. 
 
 
 
Figure 4.43: Colony PCR and double digest control for hGR TALEN pair after Golden 
Gate reaction #2. 
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4.2.3. Expression of hGR TALEN pair in HCT116 cells and detection of mutation 
 
After the assembly of the TALEN pair was complete, we transfected adherent 
human colonic carcinoma cell line HCT116 with them using PEI transfection method. 
We incubated them at 32oC for 72 hours and extracted their genomic DNA to perform 
RFLP assay. As shown in Figure 4.44 there is a faint uncut band in transfected sample, 
indicating that the TALEN pair had induced mutation.  
 
Figure 4.44 RFLP assay for hGR TALEN transfected HCT116 WT cells. Red arrow 
show the uncut band caused by the presence of mutation. 
 
 
4.2.4. Construction of homologous donor plasmid to insert Venus gene into hGR 
endogenously 
 
 In order to induce gene knock-in at the translation start site of the glucocorticoid 
receptor gene we designed a donor plasmid that is homologous to the gene at both ends, 
and the middle part included the insert. Overall, there were four main different PCR 
products that were supposed to be joined; the left homologous arm, puromycin 
resistance gene, Venus-YFP gene and the right homologous arm. The strategy to 
assemble this product is explained in Figure 3.2 of the Methods section. Venus gene and 
the puromycin resistance gene have around 600bp long sequences therefore while 
designing left and right homologous arms we arranged them to have at least similar 
lengths to promote more accurate homologous recombination. Left arm was designed to 
have the whole promoter region before the start codon of the hGR gene so that when the 
two other genes were integrated into the genome at that point the start codon of the 
puromycin resistance gene would be the new start point of the translation. In order to 
have the expressed region of the hGR fused to the Venus gene the right homologous 
arm began with the start codon of the hGR, being planned to be attached right at the end 
of the Venus gene. The positions of the left and the right homologous arms on the hGR 
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gene are shown in Figure 4.45 and Figure 4.46. The forward primer of the left arm had 
NheI restriction enzyme cut site and the reverse primer of the right arm had BamHI cut 
site added on their 5’ ends to ligate them to a plasmid when the whole product was 
assembled. We PCR amplified both regions with Phusion Polymerase enzyme for high 
fidelity and to avoid overhang ends. The agarose gel images of the PCR results are 
shown in Figure 4.47. 
 
 
 
Figure 4.45 Left homologous arm PCR site on hGR gene locus. Gray arrows indicate 
the primers that are used to amplify the left homologous arm which is 627bp long. Light 
green arrow show the 2nd exon and the yellow arrow indicate the start codon. TALEN 
pair which are shown by purple arrows are at the downstream of the start codon. 
86 
 
 
Figure 4.46 Right homologous arm PCR site on hGR gene locus. Dark green arrows 
indicate the primers that are used to amplify the right homologous arm which is 594bp 
long. Light green arrow show the 2nd exon and the yellow arrow indicate the start codon. 
TALEN pair which are shown by purple arrows are at the downstream of the start codon. 
 
 
 
 
 
Figure 4.47 The optimized PCR results of left and right homologous arms of hGR gene. 
The regions were amplified from HCT116 genomic DNA extract. 
 
We amplified the puromycin resistance gene from hAAVS-SA2A which was a 
donor plasmid used in another study 40. We added a ~20bp homologous site to the left 
arm’s 3’ end on the 5’ end of the puromycin forward primer, and P2A sequence on the 
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5’end of the puromycin reverse primer. P2A is a self-cleaving peptide that has a ~60bp 
sequence which enables preceding and following genes’ translation occur without 
ribosome detaching from the mRNA but as soon as the translation is complete the 
product is cleaved from this site, separating the two proteins from each other 80. We did 
not include the stop codon to the reverse primer of the puromycin resistance gene so 
that the translation would continue with the Venus gene without interruption but we put 
P2A sequence in between so that they would not be joined with Venus fluorescent 
protein. We amplified the Venus gene from mVenusC1, a plasmid modified from a YFP 
expressing vector 81 and has no stop codon so that it could be attached to a protein that 
follows it. The venus forward primer had P2A sequence on its 5’ end as the 
puromycin’s reverse primer. The reverse primer of the venus gene was homologous to 
the right homologous arm’s forward primer on its 5’end. The plasmid maps and the 
optimized PCR results for puromycin resistance gene and the venus gene are shown in 
Figure 4.48 and Figure 4.49.  
 
 
Figure 4.48 The plasmid map and optimized PCR result for puromycin resistance gene 
40. Forward primer is homologous to the left homologous arm’s reverse primer on the 5’ 
end and the reverse primer includes P2A sequence on its 5’ end. 
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Figure 4.49 The plasmid map and optimized PCR result for Venus gene 81. The forward 
primer includes P2A sequence on the 5’end and the reverse primer is homologous to the 
forward primer of the right arm on the 5’end. 
 
After the PCR amplification for all four regions were complete we gel extracted 
them for purifying them from their primers and using the respective products as 
template we joined left arm and the puromycin resistance gene using left arm’s forward 
primer and puromycin’s reverse primer only; and we joined venus and right arm by 
using venus’ forward primer and right arms reverse primer in a second PCR reaction. 
(Figure 4.50a) After gel extracting the correct bands we performed restriction digestion 
to the fused PCR products with Kpn2I enzyme; expecting to see bands around 750bp 
and 550bp for left arm-puromycin fusion, and around 750 and 650bp for venus-right 
arm fusion. (Figure 4.50b) Since we could not join the two products in a final PCR 
reaction instead we used Gibson Assembly protocol which was explained in Figure 3.3 
to assemble the final product. (Figure 4.50c) Even though the ligation of the four PCR 
products are complete we could not yet clone it to a final plasmid, however the final 
design we aimed to construct is shown in Figure 4.51.  
89 
 
 
Figure 4.50 The experiments done to fuse PCR products of the hGR donor plasmid. The 
correct bands are shown with red arrows. 
 
 
 
 
Figure 4.51 The plasmid map for the hGR donor construct. The gray arrow shows left 
homologous arm, the blue arrow shows puromycin resistance gene, the orange site that 
follows it is the P2A sequence, the yellow arrow indicates the venus gene and the green 
arrow is the right homologous arm, which is the second exon of the hGR gene. 
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       5.  DISCUSSION 
 
 
Transcription activator-like effector (TALE) proteins from the plant pathogen 
Xanthomonas are recently discovered DNA binding proteins that are composed of 
highly conserved repeat modules in their DNA binding central domain. Each repeat 
module is consists of 34 amino acids and they are polymorphic on the 12th and 13th 
amino acid residues which are called repeat variable di-residues (RVDs). The 
specificity of the DNA binding domain (DBD) is determined by a simple one RVD - 
one base code and modularity of this protein structure allows assembly of domains that 
can target any site in the genome. TALE nucleases (TALENs) were developed by the 
fusion of the catalytic domain of the FokI restriction enzyme to DBD of the TALE 
protein and now they are being used as tools for efficient genome modification 1,2. 
 
Interleukin-7 signaling is crucial for development, differentiation and survival of 
lymphocytes. The expression of IL-7 receptor in lymphocytes changes during 
development. Upstream promoter and enhancer regions of the IL-7Rα gene locus 
contain binding sites for transcription factors that have roles in regulating this 
expression 63,65,66,70. Also, the gene locus contains an evolutionarily conserved region 
with a potential silencer at the intronic region in between the 2nd and the 3rd exons. We 
mutated the binding sites of two transcription factors, glucocorticoid receptor (GR) and 
Notch, and we aimed to delete the entire 2nd intron to understand the roles of these sites 
in the regulation of IL-7Rα gene expression in T lymphocytes. Glucocorticoids are 
immunosuppressive and anti-inflammatory agents that signal through glucocorticoid 
receptor and have various effects on growth, differentiation and function of 
lymphocytes 72. For this reason, along with the GR binding site in the IL-7R gene locus 
we targeted the translation start site of the glucocorticoid receptor gene itself, both for 
generating knockout cells that we could conduct experiments in the deficiency of GR 
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and to generate fluorescent GR proteins that could be visually tracked within the cell by 
inserting a Venus-YFP gene at the same locus and promoting their co-expression.  
 
 For our experiments we designed and constructed 5 pairs of TALENs and in all 
of them we paid attention to similar points, aiming to assemble the pairs that would bind 
the target with high specificity and would function efficiently. To avoid TALENs’ off-
target effects, they should only be expressed in the cells transiently; the presence of 
TALENs are no longer necessary after the double strand break (DSB) is induced and 
their continuous activity would not only increase the risk of other sites in the genome 
being targeted, but also would be deleterious to the mutations induced in the targeted 
site, preventing the generation of a stable mutant genotype. For this reason we cloned 
the TALEN repeats to eukaryotic expression plasmids and expressed these TALENs 
ectopically. Previous studies showed that the amino acid sequences flanking the DNA 
binding domain could affect the binding efficiency of the protein and the distance 
between the DBD and FokI cleavage domain in the C-terminal could be an important 
factor in their dimerization and catalytic activity. Goldy TALEN backbone was 
generated to optimize TALEN activity with truncations in the N and C terminal regions 
and was shown to be very efficient 34,42. Therefore, we used Goldy TALENs as our 
expression plasmids in all of the constructs. As RVDs, we used NI, NG, HD for adenine, 
thymine, and cytosine base recognition respectively. In Notch TALEN experiments NN 
was used for binding the G nucleotide due to its high binding efficiency compared to 
other guanine binding RVDs. However, to avoid possible off-target effects we switched 
to NH RVD for TALEN constructions that were generated later on since NH was 
reported to be more specific than NN even though it is less efficient in binding 9,15. The 
length of the spacer region in between two TALEN binding sites is another factor that 
affects the dimerization and catalytic activity of the FokI domain, and recent studies 
show that a 15-16 bp long spacer is the optimum spacer length for most efficient 
TALEN activity 82. While constructing the TALENs in these experiments we took these 
parameters into account.  
 
Detection of the TALEN induced mutations was challenging. After we obtained 
a TALEN introduced pool of cells, we performed restriction fragment length 
polymorphism (RFLP) assays to determine the efficiency of TALEN activity. The 
principle of this strategy is to have a restriction enzyme cut site in the targeted region. 
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Induced deletions and insertions (INDELs) disrupt the region, destroy the restriction 
enzyme (RE) recognition sequence and block REs from digesting this target from 
amplified PCR products, appearing as an uncut band. However, not all of the targeted 
sites conveniently had restriction enzyme cut sites right in the middle, and considering 
that most of the mutations induced would span a small site, it is very likely that some of 
the mutations could not be detected because they did not affect the RE recognition site. 
For instance, we could only detect a very faint uncut band in hGR TALEN transfected 
HCT116 cells (Figure 4.44). The recognition site for the MboII enzyme only spanned a 
region on the left side of the spacer; therefore, we could not detect INDELs appearing 
on the right side (Figure 4.39). These kinds of parameters make it difficult to determine 
the efficiency of TALEN activity and detect the presence of mutations.  
 
We used RLM11 cells, a CD4 single positive thymoma cell line which has high 
IL-7R expression levels on their membranes for observing the effects of induced 
mutations, assuming that it could easily be detected by the changes on the expression 
phenotype. However, the IL-7R expression level comparison of TALEN induced cell 
pools did not yield reliable results because it took a long time for the cells to recover 
after electroporation and 32°C incubation for three days. We subjected cells to transient 
hypothermia (32°C incubation) after TALEN transfection because it was shown that this 
could increase the mutation efficiency both by zinc finger nucleases and TALENs 10,83 
probably by increasing the folding efficiency of the proteins and slowing down the 
progression of the cell cycle. Another problem was the difficulty of sorting the small 
populations of cells due to the low efficiency of genomic mutations. When we 
compared IL-7R expression levels by flow cytometry right after the transfection and 
32°C incubation we saw that GFP control plasmid transfected cells also had much lower 
IL-7R levels in most of the experiments (Figure 4.9). When we waited for a few splits 
for cells to recover and eliminate the effects of transfection, we observed that the 
transfected pools did not have any significant difference in their IL-7R expression levels 
compared to wild type cells.  It was likely that we lost various types of mutations during 
the splits, and in case the mutant cells had any disadvantage of growing, the WT cells 
within the pool could take over the population. For this reason, we decided to grow 
single cell colonies from both GR and Notch binding site targeting TALEN introduced 
pools so that we could detect their specific mutations and directly correlate a mutation 
with a phenotype.  
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 We screened for GR transcription factor binding site mutated RLM11 single cell 
colonies by the RFLP assay and we found 5 colonies that give an uncut band upon 
digestion. We analyzed their mutations by DNA sequencing and confirmed that all the 
mutations had occurred in the GR binding site (Figure 4.13). When we compared their 
IL-7R expression levels to WT cells we realized that most of the cells had higher 
expression levels than the WT in repeated experiments except for the 10th colony 
(Figure 4.14). These results were unexpected because glucocorticoid treatment is used 
to induce IL-7R expression and GR was shown to bind to this location to positively 
regulate the IL-7R expression in cells that do not express IL-7R 73. It is possible that GR 
signaling does not have a role in the regulation of IL-7R gene expression in late stage 
thymocytes that express IL-7R stably and maybe even has suppressing effects even 
though we cannot confirm this only with the present results.  The 10th colony on the 
other hand probably has lower IL-7R levels because it had a large deletion (19bp) in the 
targeted site, which is likely to disrupt a neighboring TF binding site of a positive 
regulator. We repeated this experiment with 3B4 cells which do not normally express 
IL-7R, but can be stimulated by glucocorticoid treatment; however, we had to 
discontinue the experiments due to the low efficiency of transfections. We think that 
disruptions induced on the GR binding site we targeted would prevent the complete 
activation of IL-7R expression in these cells.  
 
 It was more challenging to screen for Notch transcription binding site mutated 
single cell colonies than the GR mutated ones. If we take uncut bands in their RFLP 
analysis results as an indicator of mutation rate, around 20-25% of the GR binding sites 
in the pool genome were mutated while this percentage was only around 5% for the 
Notch TALENs. For that reason while screening for mutated single cells we eliminated 
a portion of them by flow cytometric analysis selecting only colonies with lower IL-7R 
expression levels compared to WT cells (Figure 4.18). We assumed that the mutated 
colonies would be among these IL-7Rlow cells. We performed an RFLP assay on the 
selected colonies and found only two of these to be mutated (Figure 4.19). While doing 
these experiments we realized that growing colonies from a single cell reduces their 
health and recovery takes a long time. Most of the cells we selected at first probably had 
lower expression only due to the growth conditions. Upon further culturing, most clones 
recovered their IL-7R expression. However, a few clones still had significantly lower 
IL7R expression levels than the WT pool. We analyzed the mutation status of these 
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clones by DNA sequencing. We predicted that these clones might have a mutation that 
could not be detected by RFLP. However, only the 35th colony had mutations in the 
Notch binding site and all the others, including the ones with lowest IL-7R expressions 
(clone 30th and 74th) had intact GR binding sites (Figure 4.21). The 74th colony was the 
most interesting one among the colonies because it had a knock-out phenotype; 
however, both RFLP and the sequencing results indicated that it had no mutations. We 
hypothesized that this could result from a very large deletion in the locus that prevents 
the amplification of the region by PCR. Therefore, we also PCR amplified the region 
with primers that span a larger area in the locus. However, we still observed only the 
WT bands (Figure 4.23). We do not yet know the reason for the loss of expression in 
these cells. The phenotype we observe might be due to an even larger deletion that we 
could not detect or it could be because of an off-target activity of the TALEN pair, 
resulting in the disruption of an alternative locus important for IL7R expression. With 
these experiments, we show that the Notch site mutated colony #35 and #49 have 
significantly reduced IL7R expression levels compared to WT cells, yet we do not know 
why IL-7R expression in the other few cells had decreased or whether there were any 
mutants among the ones that had normal IL-7R levels. 
 
Another problem about the interpretation of the results we obtained with both 
the GR and Notch binding site targeting experiments was the unknown ploidy of the 
RLM11 cancer cells. Even though we grew single cells to eliminate the WT phenotype, 
most of the mutations induced seemed to be monoalleic and even clones with two types 
of mutations also contained an intact WT. The GR binding site mutated cell colony #15 
had two types of deletions (Figure 4.13) and even though it was barely visible in RFLP 
results there we also observed a WT sequence, which was confirmed by sequencing 
analysis. In a similar way, colony #35 from Notch binding site targeted cells had one 
insertion and one deletion (Figure 4.21). Yet, a third WT sequence appeared in both the 
RFLP and sequencing analyses. This could be due to a low frequency WT population in 
the clone; a WT cell that possibly arising from adhered to the mutant cell when single 
cells were separated into different wells. This WT contaminant might have started to 
divide much later and still might be appearing as a small portion of the clone. 
Alternatively, these results could be due to presence of at least three alleles, which will 
be confirmed by SKY karyotype analysis. If the latter is the case, then the mutant 
colonies with one type of mutation have at least two of their alleles intact, and due to 
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this reason their phenotype might not be getting affected by the mutation. Nonetheless, 
at least two of the alleles in colonies #11 and #15 of the GR site experiments were 
mutated. The same situation is valid for the 35th colony of Notch experiments.  
 
 For the experiments where we targeted the 2nd intron of the IL-7R gene, we 
showed that even with co-expression of two TALEN pairs we could induce double 
strand breaks. However, in that cell pool it is likely that these mutations were not 
induced in the same cells or it is also possible that even when they were in the same 
cells, one pair might have induced the DSB after the other was repaired and sealed back. 
Nonetheless, we observed by the RFLP assay that in comparison to control experiments 
performed with only one of the TALEN pairs, the uncut band was fainter for the co-
transfection experiments (Figure 4.36). This might either indicate that a small portion of 
the mutated cells contained DSBs induced simultaneously and that the locus in between 
the two target sites was deleted, or that the DSBs were repaired by homologous 
recombination due to the presence of donor DNA. We performed PCR with the forward 
primer of the exon 2 and the reverse primer of the exon 3 in order to detect if the 
truncated product. Even though we observed the band one split after the incubation of 
the cells, it most likely belonged to the donor DNA; a few splits later we did not 
observe any bands in the pool. We have also grown single cell colonies from the first 
pool and currently screening for the correct mutations.  
 
 For the last part of the study we aimed to insert a Venus-YFP gene to the 
translation start site of the glucocorticoid receptor in order to promote their co-
expression endogenously and create a model that we could track GR protein activities 
within the cell visually. Even though the homologous recombination rate is smaller than 
NHEJ, when TALENs are used with selectable markers such as antibiotic resistance, the 
detection of mutation becomes much simpler. There are examples of studies using 
reporter systems in which a selectable marker is expressed only when mutations are 
generated at the TALEN target site 40,84. For that reason, while designing the donor 
plasmid we also included a puromycin resistance gene in between the left homology 
arm and the Venus gene so that when the donor DNA is integrated into the genome 
through homology directed repair, the first translation start codon would belong to the 
puromycin resistance gene. Because there were no stop codons in between them, Venus 
and GR would be translated along with the puromycin gene. We inserted a small P2A 
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sequence in between the Venus and puromycin genes which would permit the 
translation of the mRNA without detachment of the ribosome in the middle, but would 
have puromycin polypeptide cleaved off from the Venus-hGR fusion protein 
immediately after the translation. So far, we confirmed that the TALEN pair targeting 
the site is functional (Figure 4.44). However, even though we constructed the final 
donor product, it is yet to be cloned into a plasmid for transfection experiments.  
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6.  CONCLUSION 
 
In this study, we aimed to induce various types of mutations in the IL-7Rα and 
GR gene loci using TALEN technology. Firstly, we targeted the IL-7R gene enhancer 
and intronic sites in order to understand the functional role of two transcription factor 
sites in the enhancer region and a possible silencer site in the intronic region. The 
literature indicates that the enhancer of the IL-7R is bound by several transcription 
factors. We targeted two of these sites, GR and Notch. We constructed TALEN proteins 
that target the binding sites of these transcription factors in the IL-7R enhancer and 
examined the effects on gene expression. We generated single cell clones that contain at 
least one mutated IL-7R allele in the murine RLM11 cell line. We found that targeting 
the Notch site downregulated IL-7R expression. On the other hand, targeting the GR 
binding site did not significantly downregulate IL-7R expression in this cell line. In 
addition to these transcription factor binding sites, we targeted an evolutionarily 
conserved region in intron 2 of the IL-7R gene. For this purpose, we constructed 
TALEN pairs against exon 2 and exon 3 of the gene to induce simultaneous double 
strand breaks at these sites. We demonsrated that these TALENs can actively generate 
mutations in these sites. However, we have not yet completed the generation of a 
mutant IL-7R allele that has deleted the ECR in intron 2.  
 
 In the second part of the study, we targeted the GR gene itself. In order to knock 
out the activity of this gene, we constructed TALEN pairs targeting the translation 
initiation site. These TALENs can effectively generate INDEL mutations in this locus, 
resulting in frameshift mutations. We also targeted the same locus by homology 
directed repair to insert a Venus fluorescent protein gene in frame with the GR cDNA. 
Targeting of this gene locus is not yet complete. However, a Venus-YFP-GR fusion 
protein encoded by the endogenous GR gene locus will generate a model that will allow 
us to track GR activity visually. In conclusion we generated 10 different constructs 
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encoding five different TALEN pairs targeting either the coding region or enhancer 
sequences of two immunologically important genes. These TALENs are functional and 
can efficiently introduce INDEL mutations in the genomes of tissue culture cell lines. In 
this thesis we demonstrate that TALEN induced genome editing is an effective tool to 
study the functional significance of cis regulatory regions in the genomes of tissue 
culture cell lines.  
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APPENDIX 
 
 
APPENDIX A: Chemicals Used in the Study 
 
Chemicals Supplier Company 
Acetic Acid Sigma, Germany 
Agarose Sigma, Germany 
Ampicillin sodium salt Cellgro, USA 
Boric acid  Molekula, UK 
Calcium chloride  Sigma, Germany 
Distilled water  Milipore, France 
DMEM  Gibco, USA 
DMSO  Sigma, Germany 
EDTA  Sigma, Germany 
Ethanol  Sigma, Germany 
Ethidium bromide  Sigma, Germany 
Fetal Bovine Serum (FBS) Lonza, Switzerland 
Glycerol  Sigma, Germany 
HBSS  Gibco, USA 
Hydrochloric Acid  Sigma, Germany 
Isopropanol  Sigma, Germany 
LB Agar  BD, USA 
LB Broth  Sigma, Germany 
L-glutamine  Hyclone, USA 
Liquid nitrogen  Karbogaz, Turkey 
2-mercaptoethanol  Sigma, Germany 
Penicillin-Streptomycin  Sigma, Germany 
PIPES  Sigma, Germany 
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PBS  Sigma, Germany 
RNase A  Roche, Germany 
RPMI 1640  Gibco, USA 
SDS  Sigma, Germany 
Sodium Azide  Amresco,USA 
Spectinomycin  Sigma, Germany 
Tris base  Sigma, Germany 
Trypan Blue  Fluca, Germany 
Trypsin-EDTA  Gibco, USA 
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APPENDIX B: Equipment Used In the Study 
 
 
Equipment  Company 
Autoclave  Priorclave, UK 
Balance  Sartorius, BP221S, Germany 
 Schimadzu, Libror EB-3200 HU, Japan 
Centrifuge Hitachi, Sorvall RC5C Plus, USA 
 Eppendorf, 5415D, Germany 
 Eppendorf, 5418R, Germany 
 Beckman Coulter, Allegra®X-15R, USA 
CO2 Incubator Binder,Germany 
Deepfreeze  -80°C, Forma,Thermo ElectronCorp.,USA 
 -20°C,Bosch,Germany 
Distilled Water Millipore, Elix-S, France 
Electrophoresis Apparatus Biorad Inc., USA 
 VWR, USA 
Electroporator Invitrogen, Neon Transfection Systems, USA 
Flow Cytometer BD FACS Canto,USA 
Gel Documentation Biorad, UV-Transilluminator 2000, USA 
Heater Thermomixer Comfort, Eppendorf, Germany 
Hematocytometer Hausser Scientific,Blue Bell Pa.,USA 
Ice Machine Scotsman Inc., AF80, USA 
Incubator Memmert, Modell 300, Germany 
Laminar Flow Kendro Lab. Prod., Heraeus, HeraSafe HS12, 
Germany 
Liquid Nitrogen Tank Taylor-Wharton,3000RS,USA 
Magnetic Stirrer StuartTM,SB162, UK 
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Microliter Pipettes Gilson, Pipetman, France 
Microscope Olympus IX70, Japan 
 Olympus CK40, Japan 
Microwave Oven Bosch, Germany 
pH meter Mettler Toledo, S220 SevenCompactTM 
 pH/Ion, USA 
Refrigerator Bosch,Germany 
Shaker Incubator New Brunswick Sci., Innova 4330, USA 
Spectrophotometer Amersham Biosciences, UK 
Thermocycler Eppendorf, Mastercycler Gradient, 
Germany 
Vortex Velp Scientifica,Italy 
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APPENDIX C: DNA Molecular Weight Marker 
 
 
Gene RulerTM DNA Ladder Mix 
Fermentas, Germany 
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